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SUPPLEMENTARY FIGURES LEGENDS 
Fig. S1. Gating strategy for intracellular cytokine staining (ICS) in whole blood assay. Numbers 
within the various gates indicate the percentage of T cells from a representative volunteer. 
Fig. S2. BCG specific CD4+ responses. CD4 T-cells expressing IFNγ (Panel A), IL-2 (Panel B), TNFα 
(Panel C) or all 3 cytokines (Panel D) were assessed using intracellular cytokine staining in whole blood 
assay. Data are expressed as % total CD4+ T-cells at D0, D28, D90 and D210. Numbers above the x axis 
indicate the number of responders per group at a given time point, when present. Friedman ANOVA test 
with Dunn’s post-test was used to compare responses within groups at different time-points with D0. 
Numbers on top of the panels indicate p values of ANOVA, stars indicate p values of post-tests, * p<0.05, 
** p<0.01, *** p<0.001. Between groups comparisons (Kruskall-Wallis test) did not show any significant 
difference between BCG and MTBVAC groups. 
Fig. S3. Polyfunctional responses in 5x105 CFU MTBVAC and 5x105 CFU BCG groups. Pies show 
the proportions of CD4+ T-cells producing any combination of IFNγ, IL-2 and TNFa in response to a 
stimulation with live MTBVAC or live BCG.  
Fig. S4. Phenotype of CD4+ T-cell memory responses in 5x105 CFU MTBVAC and 5x105 CFU BCG 
groups.  MTBVAC- (upper panels) or BCG- (lower panels) specific CD4+ T-cells expressing at least one 
cytokine were differentiated upon their expression of CD45RA and CCR7 in T central memory (TCM, 
CD45RA- CCR7+, right column) and effector memory (TEM CD45RA- CCR7-, left column). Data are 
expressed as % total CD4+ T-cells at D0, D28, D90 and D210. Numbers above the x axis indicate the 
number of responders per group at a given time point, when present. Friedman ANOVA test with Dunn’s 
post-tests was used to compare responses within groups at different time-points with D0. Numbers on top 
Spertini et al., Supplementary appendix  
 
 2 
of the panels indicate p values of ANOVA, stars indicate p values of post-test * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. Between groups comparisons (Kruskall-Wallis test) did not show any 
significant difference between BCG and MTBVAC groups. 
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SUPPLEMENTARY TABLE AND FIGURES 
Fig. S1 
Total 
CD8+
Total CD4+
Total
CD4+
Total 
CD8+
IL2+ TNFa+ IFNγ+
CD45RA+
CCR7+
IL2- TNFa- IFNγ-
Memory cells
CD45RA-
CCR7-
Tem
Tcm
Memory cells
Tem
TcmIL2+ TNFa+ IFNγ+
CD45RA+
CCR7+
IL2- TNFa- IFNγ-
CD45RA-
CCR7-
Spertini et al., Supplementary appendix  
 
 4 
 
0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0
-0 .4
-0 .2
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
0.2276 0.2561 0.0092
** *
0.0352
*
d ays
2 /9 1 /92 /9 3 /9 3 /9 3 /9
M T B V A C
5 x 1 0 3
B C G
5 x 1 0 5
M T B V A C
5 x 1 0 4
M T B V A C
5 x 1 0 5
0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0
-0 .2
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0 0.0006
***** *
0.1357 0.0719 0.0021
*
d ays
**
1 /9 3 /9 1 /9 4 /9 1 /9 1 /9 1 /9
M T B V A C
5 x 1 0 3
B C G
5 x 1 0 5
M T B V A C
5 x 1 0 4
M T B V A C
5 x 1 0 5
0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0
-2 .0
-1 .5
-1 .0
-0 .5
-0 .5
0 .0
0 .5
1 .0
1 .5
2
3
4 0.1447 0.1646 0.0331
*
0.0104
**
d ays
1 /9 1 /9 1 /9 1 /9 1 /9 1 /92 /9
M T B V A C
5 x 1 0 3
B C G
5 x 1 0 5
M T B V A C
5 x 1 0 4
M T B V A C
5 x 1 0 5
0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0 0 2 8 9 0 2 1 0
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
0 .6 0.1149 0.0615 0.0017 0.0396
*** **
3 /9 2 /9 1 /91 /9
M T B V A C
5 x 1 0 3
B C G
5 x 1 0 5
M T B V A C
5 x 1 0 4
M T B V A C
5 x 1 0 5
IF
N
- γ
+
C
D
4
 T
 c
e
ll
s
(%)
T
N
F
- a
+
C
D
4
 T
 c
e
ll
s
(%)
IL
-2
+
C
D
4
 T
 c
e
ll
s
(%)
3
 c
y
t.
+
m
e
m
o
ry
C
D
4
 T
 c
e
ll
s
(%)
A B
C D
 
 
 
 
Fig. S2 
 
Spertini et al., Supplementary appendix  
 
 5 
 
Fig S3 
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STUDY SYNOPSIS 
Title Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to 
Evaluate the Safety and Immunogenicity of MTBVAC in Comparison with BCG 
in Elispot Tb (ESAT-6, CFP10, PPD)- and, HIV-negative volunteers 
Indication/Study population Prophylactic vaccination against tuberculosis (TB)/ 
adults, aged 18 to 45 years, BCG naïve, HIV-negative 
volunteers without evidence of active or latent 
tuberculosis  
Rationale In view of the characteristics of the MTBVAC vaccine candidate and of pre-
clinical results, the current study aims to test the safety and immunogenicity 
of MTBVAC as a potential substitute for BCG vaccination. BCG 
vaccination has indeed demonstrated its major limitation in inducing 
protection against TB. Novel vaccines are essential to fight against the 
current world epidemics in tuberculosis and resistance to anti-TB drugs. 
Objectives Primary 
 To evaluate the safety and reactogenicity of live vaccine MTBVAC 
when given as primary vaccination to adults aged 18 to 45 years, 
Elispot Tb (ESAT-6, CFP10, PPD)- and, HIV-negative adults aged 18 
to 45 years 
 Secondary 
 To evaluate the cell-mediated immune (CMI) response induced by the 
candidate vaccine MTBVAC as determined by ELISPOT and 
Intracellular Cytokine Staining (ICS) 
Exploratory 
 To characterize the cell-mediated immune (CMI) response induced by 
the candidate vaccine MTBVAC as determined by cell phenotyping by 
FACS and Intracellular Cytokine Staining (ICS) 
 To evaluate the cell-mediated immune (CMI) response induced by the 
candidate vaccine MTBVAC as determined by cytokine secretion into 
supernatant (Luminex assay) 
 To evaluate the humoral immune response induced by the candidate 
vaccine MTBVAC as measured by ELISA. 
 To perform a transcriptomic analysis of the immune response to the 
candidate vaccine MTBVAC 
Study design  A Phase I, double blind, randomised, controlled single-centre study in 
Elispot Tb (ESAT-6, CFP10, PPD)- and HIV-negative adults, aged 18 
to 45.  
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Safety 
follow up 
 Type of study: safety and immunogenicity. 
 All subjects who are enrolled into the study must  
 be HIV (-1 & -2) negative 
 have no history of extra-pulmonary TB 
 have no active disease on chest X-ray 
 have no documented history of BCG vaccination or a BCG scar, 
and be ELISPOT TB negative 
 have no history of prophylaxis or chemoprophylaxis for TB.  
 Treatment allocation: up to 36 subjects (4 groups of 9) will be enrolled 
and allocated to BCG (single dose level) or to MTBVAC at different 
dose levels (3 dose levels): 
 Subjects will be randomised by group of 4 (3 verum: 1 control) 
into three cohorts to receive either the study vaccine MTBVAC (3 
different dose levels) or BCG as a control. 
 Vaccination schedule: Single intradermal vaccination in the non 
dominant arm at D0 
 Each vaccine dose will be administered staggered by cohort, 
starting with the cohort with the lowest MTBVAC dose level 
 After at least 35 days of follow-up within each cohort there will be 
a safety review and evaluation. Vaccination of the subsequent 
cohorts will occur if there are no safety issues as defined by preset 
stopping rules. 
 
 A 7-day (Day 0-6) follow-up for solicited local and general symptoms 
after vaccination (diary card). 
 Follow-up visits at day 0, 2, 7, 28, 56, 90, 150, 210 for unsolicited 
local and general adverse events (AEs) after vaccination. 
 Serious adverse events will be collected during the entire study period.  
 Duration of the study per subject: 9-10 months (screening, vaccination 
and 6 months follow-up). 
 Data collection: on paper CRF. 
Number of subjects Target enrolment of 36 healthy Elispot Tb (ESAT-6, CFP10, 
PPD)- and HIV-negative volunteers, aged 18 to 45. 
Primary endpoints 
 
Safety and reactogenicity for all subjects as determined by: 
 Occurrence of solicited symptoms during the 7-day follow-up 
period following vaccination (day of vaccination and 6 
subsequent days). 
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Safety review 
process 
 
 Occurrence of unsolicited symptoms during the 210-day 
follow-up period following vaccination (day of vaccination 
and 209 subsequent days).  
 Occurrence of grade 3 vaccine related local and general 
symptoms during the 210-day follow-up period following 
vaccination (day of vaccination and 209 subsequent days). 
 Occurrence of serious adverse events throughout the entire 
study period. Subjects will be instructed to contact the 
Investigator if they experience any SAEs during the follow-up 
phase 
 Haematological and biochemical safety test levels prior and 
after vaccination (Days 0, 2, 7, 28, 56, 90, 150, 210) in each 
group 
 Within each cohort, all AEs and biochemical and 
haematological parameters collected up until Day 35 after 
vaccination of the last subject of the cohort will be reviewed 
by the data safety monitoring board to authorize progression 
to the next sequential dose and sequential group/cohort. 
 Any safety signals as defined by pre-set stopping rules 
warranting further discussions as per protocol definitions will 
be reviewed by the data safety monitoring board. Further 
vaccination will be suspended/put on hold pending review of 
unblinded data by data safety monitoring board. 
 Further vaccination will only continue if following this 
review there are no safety issues.  
Secondary 
endpoints 
 
 
 
 
 
 
 
 
Immunogenicity assessment for all subjects as determined by: 
 The cell-mediated immune (CMI) response induced by the 
candidate vaccine MTBVAC as determined by ELISPOT on 
peripheral blood mononuclear cells (PBMC): frequency of 
IFNγ positive mononuclear cells in response to vaccine 
(ESAT-6, CFP10, PPD, BCG and MTBVAC) at screening, 
and at days 28, 210 in all cohorts 
 The cell-mediated immune (CMI) response induced by the 
candidate vaccine MTBVAC as determined by Intracellular 
Cell Staining (ICS): frequency of positive mononuclear cells 
for IL-2, TNFα and IFNγ in response to whole BCG and 
MTBVAC (overnight stimulation) at Day 0, 28, 90, 210 in all 
cohorts on blood cells. 
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Exploratory 
endpoints 
 
 
Immunogenicity assessment for all subjects as determined by 
 The cell-mediated immune (CMI) response induced by the 
candidate vaccine MTBVAC as determined by Intracellular 
Cell Staining (ICS): frequency of positive mononuclear cells 
expressing markers for memory, effector and regulatory 
subsets in response to whole BCG and MTBVAC at Day 0, 
28, 90, 210 in all cohorts. 
 The cell-mediated immune (CMI) response induced by the 
candidate vaccine MTBVAC as determined by cytokine 
secretion into supernatant (Luminex assay) of IL-2, IFNγ, 
TNFα, IL-5, IL-13, GMCSF, IL-10, TGFβ, IL-17, IL-22 in 
response to whole BCG and whole MTBVAC (overnight 
culture) as well as against selected MTB antigens (long-term 
stimulation) on PBMCs at Day 0, 28, 90, 210 in all cohorts. 
 The humoral immune response induced by the candidate 
vaccine MTBVAC as measured by ELISA against selected 
MTB antigens, PPD, BCG and MTBVAC at Day 0, 28, 56, 90, 
210 in all cohorts. 
 The transcriptomic analysis of the immune response to the 
candidate vaccine MTBVAC at Day -30, -3, 0, 2, 7, 28, 56, 
90, 150, 210 in all cohorts.. 
Version V104 21-03-2013 10 
 
 MTBVAC Clinical Trial Protocol  
 
 
TABLE OF CONTENTS 
PAGE 
STUDY SYNOPSIS ......................................................................................................... 7 
TABLE OF CONTENTS ................................................................................................ 11 
LIST OF ABBREVIATIONS ........................................................................................... 14 
GLOSSARY OF TERMS ............................................................................................... 15 
1. INTRODUCTION .................................................................................................... 17 
1.1. Background ................................................................................................ 17 
1.1.1. BCG ............................................................................................. 17 
1.1.2. A need for new anti-TB vaccines ................................................. 17 
1.1.3. The recombinant MTBVAC vaccine candidate ............................. 17 
1.2. Study rationale ............................................................................................ 21 
1.2.1. Safety and Immunogenicity: ......................................................... 21 
2. OBJECTIVES ......................................................................................................... 21 
2.1. Primary objectives ...................................................................................... 21 
2.2. Secondary objectives .................................................................................. 22 
3. STUDY DESIGN OVERVIEW ................................................................................ 22 
4. STUDY GROUPS AND COHORTS........................................................................ 23 
4.1. Number of subjects / centres ...................................................................... 23 
4.2. Inclusion criteria .......................................................................................... 24 
4.3. Exclusion criteria for enrolment ................................................................... 25 
4.4. Elimination criteria ...................................................................................... 26 
4.5. Contraindications to vaccination ................................................................. 27 
5. CONDUCT OF STUDY .......................................................................................... 27 
5.1. Ethics and regulatory considerations .......................................................... 27 
5.1.1. Institutional Review Board/Independent Ethics Committee 
(IRB/IEC) ..................................................................................... 27 
5.1.2. Informed consent ......................................................................... 28 
5.2. General study aspects ................................................................................ 31 
5.2.1. Screening process ....................................................................... 31 
5.2.2. Vaccination process ..................................................................... 31 
5.2.3. Subject identification .................................................................... 32 
5.2.4. Safety Monitoring Plan ................................................................. 32 
5.3. Outline of study procedures ........................................................................ 36 
5.4. Detailed description of study stages/visits ................................................... 38 
5.5. Sample handling and analysis .................................................................... 45 
5.5.1. Treatment and storage of biological samples ............................... 45 
5.5.2. Laboratory assays ....................................................................... 45 
5.5.3. Serology and CMI plan ................................................................ 46 
6. INVESTIGATIONAL PRODUCT AND ADMINISTRATION ..................................... 47 
Version V104 21-03-2013 11 
 
 MTBVAC Clinical Trial Protocol  
 
 
6.1. MTBVAC vaccine ........................................................................................ 47 
6.2. Dosage and administration ......................................................................... 47 
6.2.1. Reconstitution of MTBVAC .......................................................... 47 
6.2.2. Reconstitution of BCG control ...................................................... 50 
6.2.3. Administration of the MTBVAC Vaccine or BCG control ............... 50 
6.3. Storage ....................................................................................................... 50 
6.4. Treatment allocation and randomization ..................................................... 50 
6.5. Method of blinding and breaking the study blind ......................................... 51 
6.6. Replacement of unusable vaccine doses .................................................... 51 
6.7. Packaging ................................................................................................... 52 
6.8. Vaccine accountability ................................................................................ 52 
6.9. Concomitant medication/treatment.............................................................. 52 
7. HEALTH ECONOMICS .......................................................................................... 53 
8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS ..................................... 53 
8.1. Definition of an adverse event ..................................................................... 53 
8.2. Definition of a serious adverse event .......................................................... 54 
8.3. Definition of Suspected Unexpected Serious Adverse Reaction: ................ 55 
8.4. Clinical laboratory parameters and other abnormal assessments 
qualifying as adverse events and serious adverse events ........................... 56 
8.5. Time period, frequency, and method of detecting adverse events 
and serious adverse events ........................................................................ 56 
8.5.1. Solicited adverse events .............................................................. 57 
8.5.2. Solicited general AEs ................................................................... 58 
8.6. Evaluating adverse events and serious adverse events .............................. 58 
8.6.1. Assessment of intensity ............................................................... 58 
8.6.2. Assessment of causality .............................................................. 60 
8.6.3. Medically attended visits .............................................................. 61 
8.7. Follow-up of adverse events, serious adverse events/ Suspected 
Unexpected Serious Adverse Reaction (SUSAR) and assessment 
of outcome .................................................................................................. 61 
8.8. Prompt reporting of serious adverse events to Biofabri ............................... 62 
8.8.1. Time frames for submitting serious adverse event reports 
to Biofabri .................................................................................... 62 
8.8.2. Completion and transmission of serious adverse event 
reports to Biofabri ........................................................................ 62 
8.9. Regulatory reporting requirements for serious adverse events ................... 63 
8.10. Post study adverse events and serious adverse events .............................. 64 
8.11. Pregnancy .................................................................................................. 64 
8.12. Treatment of adverse events ...................................................................... 65 
9. SUBJECT COMPLETION AND WITHDRAWAL ..................................................... 65 
9.1. Subject completion ..................................................................................... 65 
9.2. Subject withdrawal ...................................................................................... 65 
9.2.1. Subject withdrawal from the study ............................................... 65 
9.3. Screen and baseline failures ....................................................................... 66 
10. DATA EVALUATION: CRITERIA FOR EVALUATION OF OBJECTIVES ............... 66 
10.1. Primary endpoints ....................................................................................... 66 
10.2. Secondary endpoints .................................................................................. 66 
Version V104 21-03-2013 12 
 
 MTBVAC Clinical Trial Protocol  
 
 
10.3. Immunogenicity assessment for all subjects as determined by 
estimated sample size ................................................................................ 67 
10.4. Study cohorts to be evaluated ..................................................................... 67 
10.4.1. Total Vaccinated cohort ............................................................... 67 
10.4.2. According To Protocol (ATP) cohort for analysis of 
immunogenicity ............................................................................ 67 
10.5. Derived and transformed data ..................................................................... 67 
10.6. Final analyses ............................................................................................. 68 
10.6.1. Analysis of demographics/baseline characteristics ...................... 68 
10.6.2. Analysis of immunogenicity .......................................................... 68 
10.6.3. Analysis of safety ......................................................................... 68 
10.7. Planned interim analysis ............................................................................. 69 
11. ADMINISTRATIVE MATTERS ............................................................................... 69 
12. REFERENCES ....................................................................................................... 70 
13. APPENDIX A : ........................................................................................................ 71 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI .............................. 71 
14. APPENDIX B: ......................................................................................................... 75 
INVESTIGATOR'S AND SPONSOR'S RESPONSIBILITIES ......................................... 75 
15. APPENDIX C : ....................................................................................................... 95 
VACCINE SUPPLIES, PACKAGING AND ACCOUNTABILITY ..................................... 95 
 
Version V104 21-03-2013 13 
 
 MTBVAC Clinical Trial Protocol  
 
 
LIST OF ABBREVIATIONS 
Ab Antibody 
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
BCG Bacillus Calmette-Guérin  
BUN Blood Urea Nitrogen 
CBC Complete Blood Count 
CRF Case Report Form 
ELISA Enzyme-linked immunosorbent assay 
ELISPOT Enzyme-linked immuno-spot assay 
HBsAg Hepatitis B Surface Antigen 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
ICS Intracellular Cytokine Staining 
IFN-γ Interferon-Gamma 
Ig Immunoglobulin 
IL Interleukin 
MedDRA Medical Dictionary for Regulatory Activities 
Mtb Mycobacterium tuberculosis 
MTBVAC Recombinant Mycobacterium tuberculosis 
PBMC Peripheral Blood Mononuclear Cell 
PBS Phosphate Buffered Saline 
PPD Purified Protein Derivative 
SSRI Selective serotonin re-uptake inhibitor 
SUSAR Suspected Unexpected Serious Adverse Reaction  
Th1/Th2 T helper cell (type 1 or type 2) 
TNF-α Tumor necrosis factor – alpha 
TB Tuberculosis 
WHO World Health Organization 
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GLOSSARY OF TERMS 
Adverse event: Any untoward medical occurrence in a patient or clinical 
investigation subject, temporally associated with the use of 
a medicinal product, whether or not considered related to 
the medicinal product.  
An AE can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding), symptom, 
or disease (new or exacerbated) temporally associated with 
the use of a medicinal product.  For marketed medicinal 
products, this also includes failure to produce expected 
benefits (i.e. lack of efficacy), abuse or misuse. 
Study Advisor: An individual assigned by Biofabri who is responsible for 
advising the sponsor to achieve the study objectives. 
Eligible: Qualified for enrolment into the study based upon strict 
adherence to inclusion/exclusion criteria. 
Evaluable: Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, included 
in the according-to-protocol (ATP) analysis (see Sections 
4.4 and 10.4 for details on criteria for evaluability). 
Investigational product: A pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, 
including a product with a marketing authorization when 
used in a way different from the approved form, or when 
used for an unapproved indication, or when used to gain 
further information about an approved use.  
Clinical and Regulatory 
Affairs Monitor: 
An individual medically qualified to assume the 
responsibilities of the sponsor (Biofabri) especially in 
regards to the ethics, clinical safety and regulatory affairs 
of a study and the assessment of adverse events. 
Protocol amendment: ICH defines a protocol amendment as: “A written 
description of a change(s) to or formal clarification of a 
protocol.” Biofabri further details this to include a change 
to an approved protocol that affects the safety of subjects, 
scope of the investigation, study design, or scientific 
integrity of the study. 
Protocol administrative 
change: 
A protocol administrative change addresses changes to 
only logistical or administrative aspects of the study.  
N.B. Any change that falls under the definition of a 
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protocol amendment (e.g. a change that affects the safety 
of subjects, scope of the investigation, study design, or 
scientific integrity of the study) MUST be prepared as an 
amendment to the protocol. 
Randomization: Process of random attribution of treatment to subjects in 
order to reduce bias of selection 
Solicited adverse event: Adverse events (AEs) to be recorded as endpoints in the 
clinical study. The presence/occurrence/intensity of these 
events is actively solicited from the subject or an observer 
during a specified post-vaccination follow-up period. 
Study Monitor: An individual assigned by the sponsor who is responsible 
for assuring proper conduct of a clinical study. 
Subject: Term used throughout the protocol to denote an individual 
that has been contacted in order to participate in the clinical 
study, either as a recipient of the investigational product(s) 
or as a control. 
Treatment: Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or 
placebo intended to be administered to a subject, identified 
by a unique number, according to the study randomization 
or treatment allocation. 
Randomization 
number: 
A unique number identifying a treatment to a subject, 
according to the study randomization for treatment 
allocation. 
Unsolicited adverse 
event: 
 
 
 
Suspected Unexpected 
Serious Adverse 
Reaction or SUSAR: 
 
Any adverse event (AE) reported in addition to those 
solicited during the clinical study. Also any “solicited” 
symptom with onset outside the specified period of follow-
up for solicited symptoms will be reported as an 
unsolicited adverse event. 
Any unsolicited serious AE that are suspected to be linked 
to the administration of the investigational product. The 
investigator will report SUSAR to the Local Ethical 
Committee and Swiss institute of the therapeutic products 
“Swissmedic” as soon as possible, 
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1. INTRODUCTION 
1.1. Background 
1.1.1. BCG 
Despite the widespread use of the current vaccine against TB, Bacillus Calmette Guérin 
(BCG), the World Health Organization (WHO) declared TB an emerging public health 
problem in 1993 that has reached alarming proportions with an estimated 9.4 million new 
cases and 1.7 million deaths reported in 2009. Respiratory (pulmonary) forms of TB are 
responsible for transmission, while the emergence of life-threatening multi-drug resistant 
(MDR) and extremely-drug resistant (XDR) strains of Mycobacterium tuberculosis is of 
even more concern, as these strains are virtually untreatable (WHO Report 2011). 
BCG is the most widely administered vaccine in humans today with more than 3 billion 
individuals immunized to date and over 100 million doses administered annually to 
infants and children worldwide (BCG Vaccine. WHO position paper) (Young and Dye 
2006). BCG is a live attenuated strain of Mycobacterium bovis effective in reducing the 
rate of severe forms of TB, including meningitis and miliary TB occurring in infants and 
children mainly in developing countries (Trunz, Fine et al. 2006). However, this live 
vaccine is inconsistent in preventing spread of pulmonary TB, the most common form of 
the disease in adolescents and adults.  
 
1.1.2. A need for new anti-TB vaccines 
In the global fight against TB, prevention is vital. There is a profound need for new 
vaccine(s) both in developing countries, where TB is endemic, and in emerging and 
industrialized countries. The long history of production, distribution and global use of 
BCG makes live vaccines cost-effective interventions with a potential of saving millions 
of lives. Such vaccines, provided they are safe, effective and affordable would have a 
tremendous impact worldwide on death and morbidity from this widespread disease (BIO 
Ventures for Global Health, 2006) (Skeiky and Sadoff 2006; Young and Dye 2006).  
 
1.1.3. The recombinant MTBVAC vaccine candidate 
1.1.3.1. The live-attenuated SO2 strain 
 Inside various European TB vaccine projects and the European Tuberculosis Vaccine 
Initiative (TBVI), Prof. Carlos Martin [University of Zaragoza (UNIZAR), Spain] and 
Prof. Brigitte Gicquel (Pasteur Institute, France) have collaboratively developed a 
uniquely attenuated strain (named SO2) from a clinical isolate of M. tuberculosis by 
inactivation of the phoP gene, which encodes the transcription factor PhoP of the two-
component system PhoP/PhoR essential for M. tuberculosis virulence. It was suspected 
that the inactivation of this virulence gene would reduce the virulence of the strain, which 
was demonstrated. The novel strain SO2 was subsequently found to be a spontaneous 
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mutant unable to synthesize the complex cell-wall lipid phthiocerol dimycocerosate 
(PDIM), which is one of the most important virulence determinants in M. tuberculosis 
with a role in host immune modulation (Camacho, Ensergueix et al. 1999; Cox, Chen et 
al. 1999). SO2 has therefore two virulence factors removed: PhoP by genetic engineering, 
and PDIM as a spontaneous mutation. 
The phoP-based PDIM deficient (PhoP-/PDIM-) strain SO2 has exhibited promising 
vaccine characteristics in the relevant animal models potentiating it as reliable prototype 
vaccine against TB disease after a single dose administration. Rigorous preclinical studies 
with SO2 have demonstrated proof of principle for adequate attenuation, safety, 
immunogenicity, and protective efficacy against respiratory forms of TB in stringent 
animal models (please refer to Investigator Brochure for detailed report).  
The protection results in different animal models show that when delivered at a single 
dose, SO2 presents promising vaccine characteristics of protection and protective 
immunity against TB disease. 
- SO2 confers protection against TB in BALB/c mice comparable to current 
BCG substrains and generates more potent cell-mediated immune 
responses.  
- In the short-term protection experiment, SO2 and BCG confer comparable 
reduction in lung bacillary burden in guinea-pigs after low-dose aerosol 
challenge. 
- In the long-term high-dose aerosol challenge study in guinea pigs, SO2 
confers superior protective efficacy compared to BCG as measured by 
survival, reduced severity of disease and lung bacterial burden. 
- In non-human primates, SO2 is safe and exhibits improved vaccine 
characteristics against TB when compared with unvaccinated controls. 
Following challenge, prototype SO2 confers survival, significant increase 
in body weight, reduced gross lung lesions and significant decrease in lung 
bacillary burden, when compared with the current BCG.  
- Immunization with SO2 results in significant expansion, differentiation 
and maintenance of Ag-specific CD4+ T cells compared to BCG-
vaccination in mice. These Ag-specific CD4+ T cells are more capable of 
differentiation into functional effector cells upon challenge with H37Rv. 
The study published by Triccas et al. (Nambiar, Pinto et al.), 2011 
provides important information on the immune correlates associated with 
protective immunity to infection with M. tuberculosis. 
 
Safety is one of the main concerns and major challenge for attenuated live vaccines. The 
safety studies conducted with prototype SO2 strain have been extensive to ensure a 
comprehensive safety profile offering assurance for the intended future use of an SO2-
based vaccine (with PhoP-/PDIM- phenotype) in humans. In particular: 
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- SO2 is fully sensitive to front-line anti-tuberculosis drug treatment 
indicating that in the hypothetical case of infection with SO2-based 
vaccines, treatment would be possible. 
- SO2 was demonstrated to be completely safe for 6 months after 
inoculation of guinea pigs with 50 times the standard dose in this species.  
- In immunocompromised SCID mice, SO2 is more attenuated than BCG by 
the intravenous route, and unable to cause disease by the aerosol route. 
- From the post-exposure infection experiment in guinea pigs and mice, 
prototype SO2 does not cause toxic or adverse events.  
 
When combined with the levels of protection achieved in BALB/c mice, guinea pigs and 
non-human primates, the extended safety and immunogenicity data position the live-
attenuated SO2 strain (PhoP-/PDIM- phenotype) as a potential and a reliable vaccine for 
human use with improved immune-stimulating properties compared with the BCG 
vaccine. Additionally, the work to date implies that specific factors associated with phoP 
expression may contribute to the relative inhibition of Ag-specific response during wild-
type M. tuberculosis infection.   
1.1.3.2. The live-attenuated MTBVAC strain 
Following the Geneva consensus on essential steps towards development of new live 
attenuated mycobacterial vaccines (Kamath, Fruth et al. 2005), UNIZAR genetically 
engineered the prototype SO2 strain to have two independent non-reverting deletion 
mutations, without antibiotic markers, in the genes phoP and fadD26, additionally 
eliminating PDIM synthesis. The final construct MTBVAC is the first vaccine developed 
according with and fulfilling the first and second Geneva consensus safety requirements 
(Walker, Brennan et al. ; Kamath, Fruth et al. 2005) with the aim to deliver on the 
Millennium Development Goal to combat TB.  
Following regulatory requirements, bridging protection and immunogenicity studies were 
carried out to demonstrate that SO2 and MTBVAC are functionally comparable.  
 
- Bridging short-term protection study in guinea pigs showed the three MTBVAC 
dose groups intended for use in clinic and SO2 gave statistically equivalent 
protection, in both the lung and spleen, compared to the BCG Danish control 
group. 
- Bridging immunogenicity data in BALB/c mice provide evidence that MTBVAC 
and its prototype SO2 are functionally comparable in their ability to induce TH 1-
type CD4+ T cell activation in mice. 
Additional safety studies in guinea pigs and SCID mice corroborate the safety profile of 
MTBVAC relative to BCG. 
- In SCID mice subcutaneous inoculation of MTBVAC at 50 times the human dose 
demonstrated comparable safety to BCG Danish and BCG Pasteur (tested at the 
same dose). 
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- In guinea pigs, absence of virulence study carried out on the working seed lot and 
two final lots showed that MTBVAC complies with Eur. Ph. requirements for lot 
release of freeze-dried BCG vaccine for human use. 
The importance of preclinical data on MTBVAC pharmacodynamics including 
biodistribution, persistence and shedding was considered and preclinical data was 
generated providing robust evidence for the similar biological activity between 
MTBVAC and the BCG vaccine, which is extensively used in clinic.  
- Six months biodistribution studies in mice showed that MTBVAC and BCG 
present comparable biodistribution profile essentially limited to draining lymph 
nodes and spleen – sites important for initiation of mycobacterial immunity. Both 
vaccines were cleared at a similar rate from these lymphoid tissues for up to 6 
months post vaccination.  
- In guinea pigs at 7 weeks post-vaccination MTBVAC and BCG could not be 
detected in spleen; however, MTBVAC was detected in draining lymph nodes. 
Since Horwitz et al. (Horwitz and Harth 2003) demonstrated that viable BCG was 
cleared from the lymph nodes between 6 and 10 weeks post-vaccination, it is 
likely that any BCG present in the animals in this study had already been cleared.  
- In gonads of male and female mice MTBVAC and BCG could not be recovered 
for up to 6 months post-vaccination.  
- MTBVAC and BCG are not excreted in urine and stool of BALB/c mice for 6 
months or in guinea pigs for up to 7 weeks post-vaccination by the intended 
clinical route, dose and volume of administration.  
- MTBVAC vaccination did not result in any detectable shedding from the site of 
vaccination of guinea pigs, except immediately following intradermal 
administration. BCG vaccination resulted in the detection of viable bacilli 
immediately following vaccination and at site opening event, which resulted in 
the detection of viable bacilli in 2/10 BCG vaccinated guinea pigs.  
Skin reactivity and local tolerance studies showed that MTBVAC is less reactogenic than 
BCG after intradermal administration (intended clinical route, dose and volume) in mice 
and guinea pigs.  
- Unlike the BCG vaccine, no significant reaction was observed at the site of 
intradermal injection over a period of 7 weeks in MTBVAC vaccinated guinea 
pigs. A vaccine site ‘opening event’ was observed only in BCG vaccinated 
animals between 20 and 26 days post-vaccination. 
- The 50-day formal intradermal toxicity study in mice showed no evidence of 
systemic toxicity following vaccination with MTBVAC, and the intradermal 
injection of MTBVAC on 2 occasions over 3 weeks to BALB/c mice was only 
associated with local inflammation at the site of administration, noted in-life and 
histologically, and a higher number of circulating white blood cells.  These 
findings were also observed with BCG. The character of the inflammatory 
response noted histologically was similar for BCG and MTBVAC, but at Day 4 
and Day 25, tended to have a higher severity grade in animals that received BCG. 
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In conclusion, improved safety and protection against M. tuberculosis has been 
demonstrated in exhaustive preclinical studies with SO2 and MTBVAC compared to 
BCG. It is hoped that extended studies with MTBVAC in humans, strengthened by the 
immunological analysis of the mechanism of action of this phoP-based PDIM deficient 
strain at the cellular level, will pave the way for the introduction of a superior vaccine to 
protect against TB. 
1.1.3.3. The live-attenuated MTBVAC manufacturing 
The Spanish vaccine manufacturer BIOFABRI, S.L. has produced and characterized the 
live MTBVAC in compliance with Good Manufacturing Practices as a freeze-dried 
preparation following the European Pharmacopoeia monograph and the WHO 
Recommendations to Assure the Quality, Safety and Efficacy of BCG Vaccines (see 
chapter 6). MTBVAC is thus well-advance to progress to first-in-human clinical 
evaluation for safety and immunogenicity as projected here. 
1.2. Study rationale 
In view of the characteristics of the MTBVAC vaccine candidate and of pre-clinical 
results, the current study aims to test the safety and immunogenicity of MTBVAC as a 
potential substitute for BCG vaccination. BCG vaccination has indeed demonstrated its 
major limitation in inducing protection against TB. Novel vaccines are essential to 
fight against the current world epidemics in tuberculosis and resistance to anti-TB 
drugs. 
The rationale for the three dose levels of MTBVAC relies on the currently used doses for 
BCG vaccination. Two low dose levels, justified by safety and previous data on animal 
immunogenicity, will be compared to BCG at its usual dose of 5 x 105 cfu, then 
MTBVAC will be compared at equivalent dose to BCG if safety is judged sufficient.  
1.2.1. Safety and Immunogenicity: 
The aim of phase Ia clinical vaccine trial is to evaluate the safety of candidate vaccine 
and characterize the immune responses elicited. Therefore, in this phase I trial, we will 
address these issues for the vaccine candidate MTBVAC administered at doses of either 5 
x 103, 5 x 104 or 5 x 105 cfu and compared it to BCG as control. 
 
2. OBJECTIVES 
2.1. Primary objectives 
 To assess the safety and reactogenicity of MTBVAC candidate tuberculosis vaccine, 
when given to healthy ELISPOT-negative adults aged 18 to 45 years.  
Refer to Section 10.1 for definition of the primary endpoints. 
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2.2. Secondary objectives 
 To assess the immunogenicity of MTBVAC candidate tuberculosis vaccine when 
given to healthy ELISPOT-negative adults aged 18 to 45 years. 
Refer to Section 10.2 for definitions of secondary endpoints. 
3. STUDY DESIGN OVERVIEW 
  
Figure 1 Global injection schedule and safety follow up  
 
 
 A Phase I, open, randomised, controlled, single-centre study in adults, aged 18 to 45, 
HIV negative, be ELISPOT TB (ESAT-6, CFP 10) negative  
 Type of study: safety and immunogenicity. 
 All subjects who are enrolled into the study must  
 be HIV (-1 & -2) negative 
 have no history of extrapulmonary TB 
 have no active disease on chest X-ray 
 have no documented history of BCG vaccination or a BCG scar, and ELISPOT  
PPD less than 100 SFU/mio cell (positive ≥ 100). 
 have no history of prophylaxis or chemoprophylaxis for TB.  
 Treatment allocation: up to 36 subjects (4 groups of 9) will be enrolled and allocated 
to BCG (single dose level) or to MTBVAC at different dose levels (3 dose levels): 
 Subjects will be randomised by block of 4 (3 verum: 1 control) into three cohorts 
to receive either the study vaccine MTBVAC (3 different dose levels) or BCG as 
a control. 
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 Vaccination schedule: Single intradermal vaccination in the non dominant arm at D0 
 Each vaccine dose will be administered staggered by cohort, starting with the 
cohort with the lowest MTBVAC dose level (Figure 1and 2) 
 After at least 35 days of follow-up within each cohort there will be a safety 
review and evaluation. Vaccination of the subsequent cohorts will occur if there 
are no safety issues as defined by preset stopping rules (Figure 1 and 2). 
Safety follow up 
 A 7-day (Day 0-6) follow-up for solicited local and general symptoms after 
vaccination (diary card). 
 Follow-up visits at day 0, 2, 7, 28, 56, 90, 150, 210 for unsolicited local and general 
adverse events (AEs) after vaccination. The final visit at day 365 will be made 
through a telephone call. If needed, a physical examination can be made and control 
biological sampling done.  
 Serious adverse events will be collected during the entire study period.  
 Duration of the study per subject: 9-10 months (screening, vaccination and 6 months 
follow-up). 
Data collection: first on paper CRF then electronic CRF. 
 
Figure 2 Detailed injection schedule and safety follow up  
 
 
First block of 4 volunteers from each cohort will be vaccinated in 2 groups of 2 
volunteers at 2 days interval. 
 
4. STUDY GROUPS AND COHORTS 
4.1. Number of subjects / centres 
Thirty-six healthy BCG naïve ELISPOT TB-negative adults aged 18 to 45 years will be 
enrolled to receive either the MTBVAC vaccine or BCG as control. 
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The study will be performed at the following centre in Switzerland: 
Centre Hospitalier Universitaire Vaudois 
Vaccine and Immunotherapy Center (BT 06) 
Av. de Beaumont 29 
1011 Lausanne Switzerland 
Screening will be completed within 60 days prior to vaccination. 
Randomization/Enrolment will take place on the day of vaccination. 
4.2. Inclusion criteria 
All subjects must satisfy the following criteria at study entry. Screening procedures must 
be completed within 60 days prior to vaccination: 
 Subjects who the Investigator believes that they can and will comply with the 
requirements of the protocol (e.g. completion of the diary cards, return for follow-up 
visits) should be enrolled in the study. 
 Subjects who have no evidence of exposition to BCG as demonstrated by a ELISPOT 
PPD assay (< 100 SFU/mio cell) along with no history of BCG vaccination and no 
BCG scar  
 A male or female between, and including, 18 and 45 years of age at the time of the 
vaccination.  
 Written informed consent obtained from the subject prior to any study procedure. 
 If the subject is female, she must be of non-childbearing potential, i.e. have a current 
tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of 
childbearing potential, she must practice adequate contraception for 30 days prior to 
vaccination, have a negative pregnancy test and continue such precautions for 2 
months after the vaccination.  
 Clinically acceptable laboratory values for blood urea nitrogen (BUN), creatinine, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatases, total bilirubin, complete blood count (CBC) and differential, 
haemoglobin, platelet count and urinalysis (leucocytes, RBC, glucose, protein). 
Clinically acceptable laboratory values prior to randomization. 
 Seronegative for human immunodeficiency virus-1 and –2 (HIV-1/2) antibodies, p24 
antigen, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibodies.  
 No evidence of pulmonary pathology (i.e. active acute or chronic pulmonary disease; 
past TB disease) as confirmed by chest X-ray*.  
*If subjects have documented evidence from a competent authority of a chest X-ray showing a reading 
of no active pulmonary disease within 6 months prior to vaccination, this need not be repeated (refer 
to section 5.2) 
 No history of extrapulmonary TB. 
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 No history of previous contact with M. tuberculosis (latent tuberculosis) as 
demonstrated by a negative ELISPOT Tb (ESAT-6, CFP10) assay. 
 
4.3. Exclusion criteria for enrolment 
The following criteria should be checked at the time of study entry. If any apply, the 
subject must not be included in the study: 
 History of allergic reactions (significant IgE-mediated events) or anaphylaxis to 
previous immunisations (any vaccine). 
 History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine. 
 History of previous administration of experimental Mycobacterium tuberculosis 
vaccines. 
 Use of any investigational or non-registered product (drug or vaccine) in another 
experimental protocol other than the study vaccines within 30 days preceding the 
vaccination, or planned use during the study period. 
 Any chronic drug therapy to be continued during the study period, with the exception 
of vitamins and/or dietary supplements, birth control pills, anti-histamines for 
seasonal allergies, SSRIs (e.g. Zoloft etc…). 
 Chronic administration (defined as more than 14 days) of immunosuppressors or 
other immune-modifying drugs within 6 months prior to the first vaccine dose such as 
systemic steroids, interleukins, systemic interferons (eg local injection of interferon 
alpha for treatment of HPV is permitted) or systemic chemotherapy. (For 
corticosteroids, prednisone of equivalent dose  ≥ 0.5 mg/kg/day are forbidden. 
Inhaled and topical steroids are allowed). 
 Administration of any immunoglobulins, any immunotherapy and/or any blood 
products within the three months preceding the vaccination, or planned 
administrations during the study period. 
 Any confirmed or suspected immunosuppressive or immunodeficient condition 
(including HIV) based on medical history and physical examination (no laboratory 
testing is required).  
Given that BCG is not recommended for use in pregnant or lactating women and the 
increased risk of BCG dissemination in individuals with underlying immune 
deficiencies, the exclusion criteria further include volunteers sharing household with 
pregnant or lactating females, children under two years of age or very old individuals, 
subjects with family history of congenital or hereditary immunodeficiency, HIV-
positive patients or subjects taking any immune-suppressive therapy, including 
systemic steroids (inhaled or nasal is permitted), interleukins or anti-interleukins, 
systemic interferons (e.g., local injection of interferon alpha for treatment of HPV is 
permitted) or systemic chemotherapy. 
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 Any condition or history of any acute or chronic illness or medication which, in the 
opinion of the Investigator, may interfere with the evaluation of the study objectives, 
e.g. the safety and immunogenicity of the vaccine.  
 A family history of congenital or hereditary immunodeficiency. Subjects who 
describe a first-degree relative with clearly documented hereditary autoimmune 
disease will be excluded. 
 A stay of more than 2 months in a highly endemic area (e.g. Eastern Europe 
(Romania, Bulgaria) and low-income countries) within 6 months prior to the 
screening visit or travel of more than 2 months foreseen in an area of high endemicity 
after the enrolment into the study.   
 History of any neurologic disorders or seizures. 
 History of chronic alcohol consumption and/or drug abuse which in the Investigator’s 
opinion would put the subject at risk. 
 Major congenital defects. 
 Pregnant or lactating female. 
 Female planning to become pregnant or planning to discontinue contraceptive 
precautions. 
 Mantoux test within the last 6 months prior to enrollment. 
 
4.4. Elimination criteria  
The following criteria should be checked at each visit subsequent to the vaccination visit. 
If any become applicable during the study, it will not require withdrawal of the subject 
from the study but may determine a subject’s evaluability in the according-to-protocol 
(ATP) analysis. See Section 10.4 for definition of study cohorts to be evaluated. 
 Use of any investigational or non-registered product (drug or vaccine) other than the 
study vaccines during the study period.  
 Use of antibiotics with anti-TB activity anytime during the trial. 
 Chronic administration (defined as more than 14 days) of immunosuppressors or 
other immune-modifying drugs during the study period. (For corticosteroids, this will 
mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are 
allowed.). 
 Administration of a live vaccine (except study vaccine) not foreseen by the study 
protocol during the period starting from 30 days before dose of vaccine and ending 30 
days after, and an inactivated vaccine within 14 days prior to and after vaccination. 
 Administration of immunoglobulins and/or any blood products during the study 
period.  
 Drug and/or alcohol abuse. 
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4.5. Contraindications to vaccination 
The following AEs constitute contraindications to administration of the study vaccine; if 
any one of these AEs occurs at the time scheduled for vaccination, the subject may be 
vaccinated at a later date. 
 Acute disease at the time of vaccination. (Acute disease is defined as the presence of 
a moderate or severe illness with or without fever). Vaccines can be administered to 
persons with a minor illness such as diarrhea, mild upper respiratory infection with or 
without low-grade febrile illness, i.e. Oral temperature < 37.5°C / Axillary 
temperature < 37.5°C  
 Oral temperature of ≥ 37.5°C / Axillary temperature ≥ 37.5°C. 
 Any confirmed or suspected immunosuppressive or immunodeficient condition. 
 
5. CONDUCT OF STUDY 
5.1. Ethics and regulatory considerations 
The study will be conducted according to Good Clinical Practice (GCP), the 1996 version 
of the Declaration of Helsinki (Protocol Appendix A), and local rules and regulations of 
the country.  
5.1.1. Institutional Review Board/Independent Ethics Committee 
(IRB/IEC) 
The IRB/IEC must be constituted according to the local laws/customs of participating 
country. The ICH Harmonized Tripartite Guideline for Good Clinical Practice 
recommends that the IRB/IEC should include: 
a At least five members. 
b At least one member whose primary area of interest is in a non-scientific area. 
c At least one member who is independent of the institution/ study site. 
Only those IRB/IEC members who are independent of the investigator and the sponsor of 
the study should vote/ provide opinion on a study-related matter. 
A list of IRB/IEC members and their qualifications should be obtained by investigator.  
This protocol and any other documents that the IRB/IEC may need to fulfil its 
responsibilities, including subject recruitment procedures and information about 
payments and compensation available to subjects will be submitted to the IRB/IEC by the 
investigator. Written unconditional approval of the IRB/IEC must be in the possession of 
the investigator and Biofabri before commencement of the study. This approval must 
refer to the study by exact protocol title and number, and should identify the documents 
reviewed and state the date of review. Relevant Biofabri’ data will be supplied by 
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Biofabri’s Clinical Development Manager to the hospital/ university/ independent 
IRB/IEC for review and approval of the protocol. Verification of IRB/IEC unconditional 
approval of the protocole and the written informed consent statement will be transmitted 
by investigator to Biofabri’s Clinical Development Manager using the standard 
notification form, prior to shipment of vaccine supplies to the site.  
No deviations from, or changes to, the protocol should be initiated without prior written 
sponsor and IRB/IEC approval/ favourable opinion of an appropriate amendment, except 
when necessary to eliminate immediate hazards to the subjects or when the change(s) 
involves only logistical or administrative aspects of the study (e.g. change of monitor[s], 
telephone number[s].) Administrative changes are submitted to the IRB/IEC for 
information only. However, written verification that the administrative change was 
submitted should be obtained. Approvals/ verifications must be transmitted in writing to 
(Biofabri’s Clinical Development Manager).  
The IRB/IEC must be informed by the principal investigator of: 
- all subsequent protocol amendments, informed consent changes or revisions of 
other documents originally submitted for review, 
- serious and/or unexpected adverse events occurring during the study, where 
required, 
- all subsequent protocol administrative changes (for information, except for US 
studies), 
- new information that may affect adversely the safety of the subjects or the 
conduct of the study, 
- an annual update and/or request for re-approval, where required, 
- when the study has been completed, where required. 
- If a trial is prematurely terminated or suspended for reasons including, but not 
limited to, safety or ethical issues or severe non-compliance, the sponsor will 
promptly inform the regulatory authorities of the termination or suspension and 
the reason(s) for the termination or suspension. If required by applicable 
regulations, the investigator must inform the IEC/IRB promptly and provide the 
reason for the suspension or termination (see Appendix B for further details).  
5.1.2. Informed consent 
In obtaining and documenting informed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to GCP and to the ethical 
principles that have their origin in the 1996 version of the Declaration of Helsinki. Prior 
to the beginning of the trial, the investigator should have the IRB/IEC’s written 
approval/favourable opinion of the written informed consent form and any other written 
information to be provided to the subjects. 
Information should be given in both oral and written form whenever possible and as 
deemed appropriate by the IRB/IEC. 
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An investigator or designate will describe the protocol to potential subjects face to face. 
The Informed Consent Form may be read to the subjects, but, in any event, the 
investigator or designate shall give the subjects ample opportunity to inquire about details 
of the study and ask any questions before dating and signing the Informed Consent Form.  
Informed Consent Form must be in a language fully comprehensible to the prospective 
subjects. Informed consent shall be documented by the use of a written consent form 
approved by the IRB/IEC and signed and dated by the subjects and by the person who 
conducted the informed consent discussion on the screening visit day. The signature 
confirms the consent is based on information that has been understood. All illiterate 
individuals will have the study, the Informed Consent Form explained to them point by 
point by the interviewer in the presence of an impartial witness. The witness will 
personally sign and date the consent form. Oral witnessed consent will replace written 
consent only in countries where the local custom is contrary or if the subject’s incapacity 
precludes this and provided that the local legal obligations are fulfilled.  
Each subject's signed informed consent form must be kept on file by the investigator for 
possible inspection by Regulatory Authorities and/or Biofabri’s collaborators. The 
subjects should receive a copy of the signed and dated written informed consent form and 
any other written information provided to the subjects, and should receive copies of any 
signed and dated consent form updates. Any amendments to the written information will 
be provided to subjects.  
Both the informed consent discussion and the written informed consent form and any 
other written information to be provided to the subjects should include explanations of 
the following: 
a That the trial involves research. 
b The purpose of the trial. 
c The trial treatment(s) and the probability for random assignment to each treatment. 
d The trial procedures to be followed, including all invasive procedures. 
e The subject’s responsibilities. 
f Those aspects of the trial that are experimental. 
g The reasonably foreseeable risks or inconveniences to the subjects and, when 
applicable, to an embryo, fetus or nursing infant.  
h The reasonable expected benefits. When there is no intended clinical benefit to 
subjects, the subjects should be made aware of this. 
i The alternative procedure(s) or course(s) of treatment/ methods of prevention that 
may be available to subjects, and their important potential benefits and risks. 
j The compensation and/or treatment available to subjects in the event of trial-related 
injury. 
k The anticipated prorated payment, if any, to subjects for participating in the trial. 
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l The anticipated expenses, if any, to subjects for participating in the trial. 
m That the subjects’ participation in the trial is voluntary and subjects may refuse to 
participate or withdraw from the trial, at any time, without penalty or loss of benefits 
to which subjects are otherwise entitled. 
n That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) 
will be granted direct access to the subject’s original medical records for verification 
of clinical trial procedures and/or data, without violating the confidentiality of 
subjects, to the extent permitted by the applicable laws and regulations and that, by 
signing a written informed consent, the subject is authorizing such access. 
o That records identifying subjects will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly 
available. If the results of the trial are published, subjects’ identity will remain 
confidential. 
p That the subjects will be informed in a timely manner if information becomes 
available that may be relevant to the subjects’ willingness for continued participation 
in the trial. 
q The person(s) to contact for further information regarding the trial and the rights of 
trial subjects, and who to contact in the event of trial-related injury. 
r The foreseeable circumstances and/or reasons under which a subject’s participation 
in the trial may be terminated. 
s The expected duration of a subject’s participation in the trial. 
t The number of subjects involved in the trial. 
u The implication for future tuberculosis testing. Upon vaccination with MTBVAC or 
BCG, volunteers may become positive in screening tests such as Mantoux tests, 
Elispot TB or interferon release assays because of an immune response against 
antigens such as ESAT-6, CFP-10 (post MTBVAC) or PPD (post BCG and 
MTBVAC). Detailed results and information on the vaccine administered will be 
indicated in the certificate delivered to all volunteers. 
The investigator will prepare a model Informed Consent Form which will embody all the 
elements described above. While it is strongly recommended that this model document be 
followed as closely as possible, the informed consent requirements given in this 
document are not intended to pre-empt any local regulations which require additional 
information to be disclosed for informed consent to be legally effective. Clinical 
judgement, local regulations and requirements should guide the final structure and 
content of the document.  
The investigator has the final responsibility for the final presentation of Informed 
Consent Form, respecting the mandatory requirements of local regulations. The consent 
form generated by the investigator, must be approved (along with the protocol, and any 
other necessary documentation) by the IRB/IEC and be acceptable to Biofabri. 
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5.2. General study aspects 
Healthy adult volunteers will be recruited by non-coercive means via poster advertising 
in the CHUV, the Lausanne Medical School, the University of Lausanne and EPFL or via 
the CHUV internal web system “intranet”. Moreover advertising letters will be sent to 
CHUV employees through “Médecine du Personnel”. 
5.2.1. Screening process 
At screening, volunteers will provide a medical history (with special attention to a review 
of pulmonary, cardiac and renal systems and prior vaccine reactions) and undergo 
physical examination and routine standard laboratory screening tests. Volunteers found to 
be seropositive for HIV and hepatitis will be counselled and referred to their regular 
health care provider for further evaluation. 
All screening tests will be performed prior to entry into the study and at any other time 
during the course of the trial judged necessary by the investigators. At screening, subjects 
will be allocated a screening number. Eligible subjects will be allocated a 
randomization number at randomization by the pharmacist. The screening number 
will also be used as patient identification number (PID) for all data collected on the 
subject during the study. 
Subjects should not have received BCG, and should be negative by ELISPOT TB. 
Chest radiographs will be used to eliminate subjects who have active Pulmonary Disease. 
In persons with latent TB infection chest radiograph is usually normal but may show 
some apical scarring. Classification as outlined by the American Thoracic Society 
(American Thoracic Society, 2000) will be used to distinguish between latent infection 
and active disease. During screening, chest X-ray will not be done for subjects who have 
had a chest X-ray done within 6 months prior to administration of the first vaccine dose, 
with a reading of no active pulmonary disease from a competent authority. 
5.2.2. Vaccination process  
The vaccine MTBVAC and the BCG control will be stored at the CHUV Central 
Pharmacy. The unique treatment number will identify the unique vaccine dose 
administered to subject. After randomization the randomization number assigns the 
subject to one group or another in a blinded way. The randomization number will be 
recorded on the Case Report Form. 
All vaccines will be administered intradermally in the non-dominant arm. Vaccinations 
will take place at the CHUV Vaccine and Immunotherapy Center. 
For each vaccination during the course of the study, a pharmacist or a qualified person 
will prepare the vaccines. The pharmacist will randomize subject to one of the treatment 
arm, and attribute to each subject a randomisation number. He will fill a blind syringe 
according to this study protocol from the vaccine vial (refer to section 6.2). The 
pharmacist will play no part in the assessment of adverse events reported by subjects.  
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The clinical investigator qualified person, i.e. a vaccinator, will give all vaccinations in a 
blind manner. The Vaccinator will receive the syringes with the appropriate vaccine dose 
as prepared and randomized by the CHUV pharmacist and will administer the vaccine to 
an enrolled subject.  
Subjects, who cannot be vaccinated on the originally scheduled date (due to an acute 
illness on the judgment of the PI or designate or scheduling conflicts), will be vaccinated 
within two months. If they cannot be vaccinated within this time period, they will have to 
pass a new screening visit. 
A staff member experienced in the resuscitation of subjects will be available at all 
vaccination sessions. Facilities and equipment will be available to give emergency 
treatment in the case of an anaphylactic reaction following administration of vaccines. 
All subjects will be observed for at least 60 minutes after the administration of vaccine to 
evaluate and treat any acute adverse events. 
Following vaccination subjects will be given diary cards to record any adverse events that 
may occur post vaccination. These diary cards are to be returned 6 days after vaccination. 
On receipt of these diary cards the investigator or designate will verify the contents and 
transcribe the information into the appropriate sections of the CRF. Any unreturned diary 
cards will be sought from the subjects through a convenient procedure by the 
investigator.  
In addition subjects will be given an ‘adverse event and medication form’ to record any 
other adverse events that may occur outside the follow-up period for solicited symptoms 
and any medication they may take up until 240 days after each vaccination. The form will 
have a section to record symptoms with their intensity and start and stop date. There will 
also be a medication section with information on the trade name, reasons for taking 
medication, the dosage and start and stop dates. The subject must be reminded to bring 
this form for each follow up visit to be discussed with the investigative team and the form 
will be returned to the investigator at subsequent vaccinations or 1 month after the last 
vaccination. 
5.2.3. Subject identification 
Screening numbers will be assigned sequentially to subjects consenting to participate in 
the study, according to the range of subject numbers allocated. 
5.2.4. Safety Monitoring Plan 
5.2.4.1. Safety Monitor 
A local safety monitor (LSM) from Centre Hospitalier Universitaire Vaudois (CHUV) will 
review volunteer safety information after each dose. This will include a systematic review of 
grade 3 and serious adverse events after each vaccination. He will not be part of the 
investigative team. The LSM will offer a recommendation following an assessment of 
adverse events and/or accompanying safety data if suspension of vaccination of following 
subjects will be required.  
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The Local Safety Monitor (LSM) will be an experienced clinician qualified to evaluate safety 
data from clinical trials of Tuberculosis vaccines. All SAEs will be reported to him/her. In 
exceptional circumstances, for example a death possibly related to vaccination, or under 
conditions as outlined below in the safety monitoring plan, he/she will have the authority to 
suspend vaccination pending discussion with the sponsor and collaborators. He will have the 
authority to request the code-break information from Biofabri (safety study contact for 
emergency code break) to unblind individuals at any time if a set of medical events requires 
unblinding to enable treatment or death related to vaccination. All unblinding should be 
reported immediately to Biofabri. Refer to section 6.5 for information on study unblinding.  
Biofabri will also appoint a Clinical Trial and Regulatory Affairs Monitor, a physician 
qualified to evaluate safety data from clinical trials of new vaccines who will review in 
parallel any blinded safety information sent to the LSM. 
5.2.4.2. Review of Safety Data by the Clinical Trial Medical and Regulatory 
Affairs Monitor 
Vaccinations per dose level of MTBVAC or control BCG are scheduled at Day 0, and 
additional safety evaluations at days 2, 7, 28, 56, 90, 150, 210 and 365 after vaccination. 
The following events must occur within the specified timeframe to ensure proceeding to 
the next vaccination as per schedule.  
• The investigative site must complete paper CRF from the day of vaccination up to 
Day 7 for each subject by Day 9. 
• LSM will receive the data by FAX or electronic doc or paper. 
• The Clinical Trial Medical and Regulatory Affairs Monitor must review the 
demographic and safety data for each subject within one week after the last subject 
has completed the 7-day follow-up after vaccination. If warranted, the CTMRAM 
recommend to the site to suspend further vaccination at least 1 business day prior to 
the next volunteers’ vaccination in case a safety signal is observed or the predefined 
holding rules are met. 
 
5.2.4.3. Vaccination process and Safety Review Team 
Subjects will be allocated to 4 groups according to randomization schedule and vaccine 
type and doses: 
D0 dose vaccination will be spread out starting initially by cohort 1 (9 volunteers 
receiving the first dose level of MTBVAC plus 3 BCG controls). The volunteers will be 
randomized by block of four (3 volunteers receiving MTBVAC plus 1 BCG control). The 
vaccination of the second and third block of four will start one week after the vaccination 
of the first member of the previous block. Vaccination within cohort 2 (9 volunteers with 
second dose level of 9 MTBVAC plus 3 BCG controls) and cohort 3 (9 volunteers with 
third dose level of MTBVAC plus 3 BCG controls) will be completed in a similar fashion 
(see figure 1 and 2, section 3).  
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Vaccinations of the three cohorts will be staggered by at least six weeks. Vaccination 
after each cohort will be followed by a safety review of data (reactogenicity, biochemical 
and haematological safety tests) collected up until 56 days post vaccination of the first 
volunteers, i.e. at least 5 weeks post vaccination of the last subject. All safety and 
reactogenicity data collected up until 5 weeks post vaccination of the last subject will be 
reviewed blinded by the Investigator group and a safety review team (SRT) to see if 
holding/suspension criteria are met. If there are no safety issues then vaccination of the 
second cohort will commence.  
The investigative site will be required to complete paper CRF from Day 0 to 56 following 
vaccination for each cohort by two weeks after the visit 7. 
A safety review team (SRT), including as core members the Clinical and Regulatory 
Affairs Monitor and Principal Investigator will be responsible for reviewing blinded 
safety data ‘in-stream’ (i.e. throughout the course of the study). The SRT must review the 
demographic and safety data for each cohort after vaccination within one week after the 
last subject has completed an at least 5 week follow-up after vaccination. If warranted, 
the SRT may instruct the site to suspend further vaccination of the next volunteers or the 
next cohort at least 1 business day prior to vaccination in agreement with the LSM and 
the investigator. 
In case a safety signal is observed or the predefined holding rules are met, the SRT leader 
is responsible for the urgent communication and escalation to Biofabri.  
 
5.2.4.4. Holding Rules 
5.2.4.4.1. Holding rules for vaccination (temporary suspension of vaccination) 
Vaccination will be put on hold/ suspended pending review of data with the SRT if 
greater than 3 vaccinated subjects from a same cohort develop severe or unexpected AEs 
judged to be related to vaccination by the Investigator within 5 weeks after the last 
subject of each cohort has been vaccinated; 
for a death-or-life threatening SAE judged to be related to vaccination by the Investigator 
at any time during the study;  
for an anaphylactic shock reaction in an enrolled subject following vaccination. 
Activation of the Holding Rule requires a thorough review by the Investigators and 
Sponsor. Vaccinations will only continue following recommendations from the SRT and 
in agreement with the Investigator. 
If for any reason, the study is stopped, the National Regulatory Agency will be informed 
by letter via the Sponsor and the Ethics Committee via the Investigator. 
Vaccination can be put on hold by Local Safety Monitor, subject to discussion with the 
investigators, BIOFABRI Clinical Development Manager, Clinical and Regulatory 
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Affairs Monitor, if after reviewing blinded safety and reactogenicity data after each 
vaccination the following criteria are met: 
• Vaccinations will be put on hold 
- if at least 3 subjects per cohort develop a Grade 3 general solicited adverse event during 
the 7 follow-up days after vaccination which persists at Grade 3 for > 48 hours (2 days). 
The 7 days includes the day of vaccination and 6 subsequent days. The general solicited 
adverse events are Fatigue, Fever, Gastrointestinal symptoms (includes nausea, vomiting, 
diarrhea or abdominal pains) and Headache or 
-  if 3 subjects per cohort develop any other Grade 3 unsolicited adverse event considered 
to be associated with vaccination during the 7 follow-up days after vaccination and 
persisting at Grade 3 for > 48 hours (2 days). The 7 days includes the day of vaccination 
and 6 subsequent days. 
• Vaccination can be put on hold for the three cohorts if any individual shows large 
ulceration (necrosis of the dermis, >1 cm in diameter) at the injection site following 
vaccination. 
5.2.4.4.2. Holding Rules for the whole study (temporary suspension of the study) 
The study should be put on hold by Local Safety Monitor at any time during the study, 
subject to discussion with the investigators, the BIOFABRI Clinical Development 
Manager, or the Clinical and Regulatory Affairs Monitor, if any subject develops one or 
more of the following 
• Hepato/splenomegaly  
• Acute lymphadenitis (swelling and or tenderness of the lymph nodes including 
cervical, axillary, inguinal and epitrochlear lymph nodes). 
• Acute pulmonary disease associated with an abnormal chest x-ray. 
• New onset of fever, weight loss or chronic cough (Fever for >1week, cough lasting 
>2months, weight loss of  >10kg) 
In the onset of any of the above, the subject will undergo a thorough laboratory and 
clinical examination to establish a diagnosis. 
5.2.4.5. Discussion Process after a vaccination or a clinical study hold 
BIOFABRI will be informed through the Clinical Development Manager or the Clinical 
and Regulatory Affairs Monitor on the same day that the LSM makes a decision to 
temporarily suspend any part of the study.  Within 5 working days of placing vaccination 
of a cohort or the clinical trial on hold, the Clinical Development Manager or the Clinical 
and Regulatory Affairs Monitor will organise a meeting (via teleconference, 
videoconference, or face-to-face) to review and discuss the safety data and the events 
leading to the hold order. Three or more days prior to this meeting, BIOFABRI will 
disseminate copies of all relevant safety data to all meeting participants. 
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5.2.4.6. Process for restarting vaccination/trial 
Although the vaccination may be put on hold temporarily, further vaccination may restart 
only if all parties (the Clinical and Regulatory Affairs Monitor, the Clinical Development 
Manager, the Sponsor’s Signatory, the LSM, the SRT and the Principal Investigator) 
agree to a resumption of vaccination. 
5.2.4.7. Process for stopping of trial 
In the event that the trial is stopped, BIOFABRI will inform the IRB through the 
investigator and Swissmedic through its representative in Switzerland. A report will be 
written detailing the rationale used for reaching this decision. 
5.3. Outline of study procedures 
The outline of study procedures is presented in Table 1. 
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Table 1 List of study procedures 
Phase Screen  Vaccination phase Post-vaccination FU Tel 
Month -2  0   1 2 3 5 7 12 
Day -60 to -3 -3 0 2 7 28 56 90 150 210 365 
Visit 1 2 3 4 5 6 7 8 9 10  
Dose   1         
Informed consent •           
Check of inclusion & exclusion criteria ○  •         
Check of elimination criteria    • • • • • • •  
Check of contraindications   •         
Medical history •           
Current medical history (anamnesis) •  • • • • • • • • • 
Physical examination •  • • • • • • • • (•) 
Resting vital signs (blood pressure, heart rate, temperature) •  • • • • • • • • (•) 
Chest X-ray •*         •** (•) 
Recording of concomitant medication pre-/post-vaccination •  • • • • • • • • • 
Pre- and post-vaccination assessment incl. temperature 
measurement •  • • • • • • • • 
 
Vaccination   •         
Diary cards Distribution   •         Return     •       
AE and medication form 
Distribution   • (•) (•) (•) (•) (•) (•)   
Return    (•) (•) (•) (•) (•) (•) •  
Post-vaccination recording of solicited symptoms   • • •       
Recording of non-serious AEs post vaccination by PI   • • • • • • • • • 
Reporting of serious AEs throughout the study by PI   • • • • • • • • • 
Microbiological analyses            
Swabs at injections site, urine and stools culture    • • • (•)*** (•)*** (•)*** (•)*** (•) 
Pregnancy test: 
β-HCG-serum (4.5 ml) 
 
•          
 
β-HCG –urine   •       •  
Biochemical and haematological analysis and virology (blood)            
BUN, creatinine, AST, ALT, bilirubin, alc. Phosp. (3 ml) •  •  • • • • • •  
CBC (2 ml) •  •  • • • • • •  
HIV, HBsAg, anti-HCV (10 ml) •           
Urinalysis (proteins, leucocytes, RBC, glucose) •  • • • • • • • •  
Immunogenicity 2ary endpoints            
ELISPOT TB (ESAT-6 / CFP10 / PPD) testing# (18 ml) •##     •    •  
ICS IL-2, TNFa, IFNg (WBA) (9 ml) @   •   •  •  •  
Exploratory endpoints            
ELISPOT (PBMC) ### •     •    •  
Cytokines in culture (PBMC) (18 ml) $   •   •  •  •  
Tem/Tcm/polyfct, FACS subsets (9ml) £   •   •  •  •  
anti–MTBVAC/MTB antibodies (3 ml)   •   • • •  •  
Transcriptomics (8 ml) & • • • • • • • • • •  
Blood volume per visit in ml: 45 8 52 8 13 70 16 52 13 70  
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Phase Screen  Vaccination phase Post-vaccination FU Tel 
Month -2  0   1 2 3 5 7 12 
Day -60 to -3 -3 0 2 7 28 56 90 150 210 365 
Visit 1 2 3 4 5 6 7 8 9 10  
Dose   1         
Cumulative blood volume (ml): 45 53 105 113 126 196 212 264 277 347  
Study  intermediate safety report / cohort       •     
Study conclusion          •  
•is used to indicate a study procedure that requires documentation in the individual CRF 
(•) is used to indicate a study procedure that requires documentation in the individual CRF If necessary 
*To be done only if the subject has no evidence of the procedure (chest X-ray) performed in the past six months 
**chest X-rays at the end of the study will be performed in all subjects. 
***Not done if two previous consecutive four weeks culture have been negative 
#ELISPOT IFNγ to Mtb PPD, ESAT-6/CFP10 made at CHUV routine lab on PBMC. 
## Results important for inclusion/exclusion in the study.  
### ELISPOT IFNγ to other Mtb antigens than PPD, ESAT-6/CFP10. 
@ : stimulation of blood cells (whole blood or PBMC) with whole mycobacteria (BCG and MTBVAC, live or lysed). 
Evaluation of the frequency of specific cells that secrete cytokine in response to the stimulation.  
$: stimulation of PBMC or whole blood with various TB preparations and antigens: lysates of rMtb, Mtb, BCG ; HBHA, 
Ag85, ESAT-6, CFP-10. Analysis by Luminex of IL-2, IFNg, TNFa, IL-5, IL-13, GMCSF, IL-10, TGFb, IL-17, IL-22. 
£: stimulation of blood cells (whole blood or PBMC) with whole mycobacteria (BCG and MTBVAC, live or lysed). 
Characterization by FACS of the various subsets of Mtb specific cells, memory and polyfunctional, by analysis of the 
markers: CD3, CD4, CD8, IL-2, TNF-a, IFNg, CD45RA, CCR7. 
&: on whole blood. Include Foxp3. 
 
It is the investigator’s responsibility to ensure that the intervals between visits/contacts 
are strictly followed. These intervals determine each subject’s evaluability in the 
according-to-protocol analyses (see Sections 4.4 and 10.4 for details of criteria for 
evaluability and cohorts to be analyzed).  
Table 2 Intervals between study visits 
Visit Intervals (Vaccination phase) Size of interval 
Visit 1 (Screening) -60 to -3 days 
Visit 2 (Day -3)  +/- 1 day 
Visit 3 (Day 0) +/- 1 day 
Visit 4 (Day 2) +/- 1 day 
Visit 5 (Day 7) +/- 1 day 
Visit 6 (Day 28) +/- 3 days 
Visit 7 (Day 56)  +/- 3 days 
Visit 8 (Day 90)  +/- 3 days 
Visit 9 (Day 150)  +/- 7 days 
Visit 10 (Day 210) +/- 7 days 
Final visit (telephone call at Day 365) +/- 14 days 
5.4. Detailed description of study stages/visits 
A description of each stage of the study, as summarized in the outline of study procedures 
(Section 5.3) is given below. 
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Visit 1: Screening (Day – 60 to Day – 3) 
• Written informed consent obtained from the subjects prior to any study procedure. 
• Check of inclusion/ exclusion criteria before enrolment (See Sections 4.2 and 4.3). 
• Recording of medical history and physical examination. 
• Assess resting (resting is defined as at least 10 minutes of rest prior to obtaining the 
vital signs) vital signs (heart rate, blood pressure & temperature). 
• Chest X-ray  
Note: If the subjects have a chest-X ray done with documented results within 6 
months prior to vaccination, they do not have to get an X-ray done at the screening 
visit. 
• Collect a total of 45 ml whole venous blood for haematology, serum chemistry, 
pregnancy and serology testing, TB status and transcriptomics. 
- 14 ml for CBC, serology testing (HIV-1/2, p24 antigen, HBsAg and HCV 
antibody) and for biochemical and haematological analyses (creatinine, ALT, 
AST, total bilirubin, alkaline phosphatases and BUN).  
- 5 ml for quantitative Beta HCG (pregnancy testing) for all female subjects. 
- 18 ml for ELISPOT TB (ESAT-6/CFP10) testing 
- 8 ml for transcriptomic analysis 
• Urinalysis (proteins, glucose, leucocytes, RBC) 
• Recording of SAEs that are related to study participation (e.g. procedures or invasive 
test) or to a concurrent medication (see section 8.4) 
Visit 2: Day-3 (±1 day)  – Transcriptomic baseline 
• Collection of a of 8 ml whole venous blood for transcriptomic analysis. 
Visit 3: Day 0 – Vaccination day 
• Check of inclusion/ exclusion criteria (See Sections 4.2 and 4.3). 
• Check contra-indication to vaccination. 
• Physical examination. 
• Assess resting (resting is defined as at least 10 minutes of rest prior to obtaining the 
vital signs) vital signs (heart rate, blood pressure). 
• Recording of any concomitant medication/vaccination. 
• Pre-vaccination assessment including temperature measurement. 
• Urine pregnancy test for all female subjects. 
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• Collection of a total of 52 ml whole venous blood prior to vaccination for the 
following analyses:  
• 5 ml for biochemical and haematological analysis (CBC, creatinine, ALT, AST, 
total bilirubin, alc. phosph. and BUN) 
• 39 ml for CMI and humoral response (refer to Table 1 for details)  
• 8 ml for transcriptomic analysis 
• Urinalysis (proteins, glucose, leucocytes, RBC) 
• Vaccination: Intradermal administration of one dose of study vaccine or control at the 
level of the deltoid muscle. See Section 6.2 for details. 
The vaccinees will be observed closely for at least 60 minutes, with appropriate 
medical treatment readily available in case of a rare anaphylactic reaction following 
the administration of vaccines. The subjects will also be instructed to contact the 
investigator immediately should they manifest any signs or symptoms they perceive 
as serious. 
• Recording of any post vaccination solicited and unsolicited adverse event. 
• Recording of any Serious Adverse Events (SAEs). 
• Diary cards will be provided to the subjects to record body temperature (axillary 
temperature) and any solicited local, general occurring after vaccination, on the day 
of vaccination and 6 subsequent days. The subjects will be instructed to return the 
completed diary card to the investigator on Day 7.  
• Distribution of an adverse events and medication form to the subjects to record any 
unsolicited adverse events and medication taken occurring throughout the study. The 
subjects will be instructed to bring the form to all subsequent visits to be discussed 
with the investigative team. 
• Distribution of material for stool and urine collection. 
Visit 4: Day 2 (±1 day) - Post vaccination follow-up visit 
• Check elimination criteria. 
• Physical examination. 
• Assess resting (resting is defined as at least 10 minutes of rest prior to obtaining the 
vital signs) vital signs (heart rate, blood pressure, temperature). 
• Recording of any concomitant medication/vaccination. 
• Post-vaccination recording of solicited and unsolicited symptoms by the investigator. 
• Recording of any SAEs. 
• Collection of 8 ml whole venous blood for transcriptomic analysis. 
• Urinalysis (proteins, glucose, RBC, leucocytes) 
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• Swab of injection site for MTBVAC culture 
• Collection of urine and stools for MTBVAC culture and distribution of material. 
• Verification of the diary card and the AE/medication forms 
Visit 5: Day 7 (±1 day) - Post vaccination follow-up visit 
• Check elimination criteria. 
• Physical examination. 
• Assess resting (resting is defined as at least 10 minutes of rest prior to obtaining the 
vital signs) vital signs (heart rate, blood pressure, temperature). 
• Recording of any concomitant medication/vaccination. 
• Collection and verification of completed diary cards.  
• Verification the AE/medication forms 
• Recording of unsolicited symptoms reported since the last vaccination. 
• Recording of non-serious adverse events. 
• Recording of any SAEs. 
• Collection of a total of 13 ml whole venous blood for the following analyses: 
• 5 ml whole venous blood for biochemical and haemotological analysis (CBC, 
creatinine, ALT, AST, alc. phosph., total bilirubin and BUN). 
• 8 ml for transcriptomics analysis 
• Urinalysis (proteins, glucose, leucocytes, RBC) 
• Swab of injection site for MTBVAC culture   
• Collection of urine and stools for MTBVAC culture and distribution of material   
Visit 6: Day 28±3 days (Month 1 post- vaccination) 
• Check elimination criteria. 
• Physical examination. 
• Collection and verification of adverse events and medication form.  
• Assess resting (resting is defined as at least 10 minutes of rest prior to obtaining the 
vital signs) vital signs (temperature, heart rate and blood pressure). 
• Recording of any concomitant medication/vaccination. 
• Recording of unsolicited symptoms reported since vaccination. 
• Recording of any post vaccination solicited and unsolicited adverse events 
• Recording of any SAEs. 
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• Collection of a total of 70 ml whole venous blood for the following analyses: 
• 5 ml for biochemical and haemotological analysis (CBC, creatinine, ALT, AST, 
alc. phosph., total bilirubin and BUN) 
• 57 ml for CMI and humoral response (refer to Table 1 for details) 
• 8 ml for transcriptomics analysis 
• Urinalysis (proteins, glucose, RBC, leucocytes) 
• Swab of injection site for MTBVAC culture 
• Collection of urine and stools for MTBVAC culture and distribution of material 
• Verification the AE/medication forms 
Visit 7: Day 56 ± 3 days (Month 2 post-vaccination visit) 
• Check elimination criteria. 
• Physical examination. 
• Collection and verification of adverse events and medication form.  
• Assess resting (resting is defined as at least 10 minutes of rest prior to obtaining the 
vital signs) vital signs (temperature, heart rate, blood pressure). 
• Recording of any concomitant medication/vaccination. 
• Recording of unsolicited symptoms reported since vaccination. 
• Recording of any post vaccination solicited and unsolicited adverse events 
• Recording of any SAEs. 
• Collection of a total of 16 ml whole venous blood for the following analyses: 
• 5 ml for biochemical and haemotological analysis (CBC, creatinine, ALT, AST, 
alc. phosph., total bilirubin and BUN) 
• 3 ml for humoral response (refer to Table 1 for details) 
• 8 ml for transcriptomics analysis 
• Urinalysis (proteins, glucose, RBC, leucocytes) 
• Swab of injection site for MTBVAC culture if necessary (the cultures for M. 
tuberculosis will stop if the results of two consecutive four weeks cultures are 
negative. Cultures will be reinstituted if local leakage reappears). 
• Collection of urine and stools for MTBVAC culture and distribution of material if 
necessary (the cultures for M. tuberculosis will stop as soon as the results of two 
consecutive four weeks cultures are negative)  
• Verification the AE/medication forms 
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Visit 8: Day 90 ± 3 days (Month 3 post-vaccination follow-up visit) 
• Check elimination criteria. 
• Physical examination. 
• Recording of any concomitant medication/vaccination. 
• Recording of unsolicited symptoms reported since vaccination. 
• Recording of any post vaccination solicited and unsolicited adverse events 
• Recording of any SAEs. 
• Collection of a total of 52 ml whole venous blood for the following analyses: 
• 5  ml for biochemical and haemotological analysis (CBC, creatinine, ALT, AST, 
alc. phosph., total bilirubin and BUN) 
• 39 ml for CMI and humoral response (refer to Table 1 for details). 
• 8 ml for transcriptomics analysis 
• Urinalysis (proteins, glucose, leucocytes, RBC) 
• Swab of injection site for MTBVAC culture  if necessary (the cultures for M. 
tuberculosis will stop if the results of two consecutive four weeks cultures are 
negative. Cultures will be reinstituted if local leakage reappears)  
• Collection of urine and stools for MTBVAC culture and distribution of material if 
necessary (the cultures for M. tuberculosis will stop as soon as the results of two 
consecutive four weeks cultures are negative)  
• Verification the AE/medication forms 
Visit 9: Day 150 ± 7 days (Month 5 post-vaccination follow-up visit) 
• Check elimination criteria. 
• Physical examination. 
• Recording of any concomitant medication/vaccination. 
• Recording of unsolicited symptoms reported since vaccination. 
• Recording of any post vaccination solicited and unsolicited adverse events 
• Recording of any SAEs. 
• Collection of a total of 13 ml whole venous blood for the following analyses:  
• 5  ml for biochemical and haematological analyses (CBC, creatinine, ALT, AST, 
alc. phosph., total bilirubin and BUN) 
• 8 ml for transcriptomics analysis 
• Urinalysis (proteins, glucose, leucocytes, RBC) 
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• Swab of injection site for MTBVAC culture  if necessary (the cultures for M. 
tuberculosis will stop if the results of two consecutive four weeks cultures are 
negative. Cultures will be reinstituted if local leakage reappears)  
• Collection of urine and stools for MTBVAC culture and distribution of material if 
necessary (the cultures for M. tuberculosis will stop as soon as the results of two 
consecutive four weeks cultures are negative) 
• Verification the AE/medication forms 
Visit 10: Day 210 ± 7 days (Month 7 post-vaccination follow-up visit) 
• Check elimination criteria. 
• Physical examination. 
• Recording of any concomitant medication/vaccination. 
• Recording of unsolicited symptoms reported since the last vaccination. 
• Recording of any post vaccination solicited and unsolicited adverse events 
• Recording of any SAEs. 
• Chest X-ray 
• Collection of a total of 70 ml whole venous blood for the following analyses: 
• 5.3  ml for biochemical and haemotological analysis (CBC, creatinine, ALT, 
AST, alc. phosph., total bilirubin and BUN) 
• 57 ml for CMI and humoral response (refer to Table 1 for details) 
• 8 ml for transcriptomics analysis 
• Urinalysis (proteins, glucose, leucocytes, RBC) 
• Urine pregnancy test for all female subjects. 
• Swab of injection site for MTBVAC culture  if necessary (the cultures for M. 
tuberculosis will stop if the results of two consecutive four weeks cultures are 
negative. Cultures will be reinstituted if local leakage reappears)  
• Collection of urine and stools for MTBVAC culture  if necessary (the cultures for M. 
tuberculosis will stop as soon as the results of two consecutive four weeks cultures 
are negative) 
• Collection and verification of the AE/medication forms 
Final visit (telephone call): Day 365 ± 14 days (Month 12 post-vaccination) 
• Current medical history (anamnesis) obtained through the telephone call  
• Recording of solicited/unsolicited symptoms 
• Physical examination if necessary based on the current history obtained through the 
telephone call 
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• Laboratories and/or radiologic investigations if necessary based on the current 
medical history obtained through the telephone call 
5.5. Sample handling and analysis 
5.5.1. Treatment and storage of biological samples 
Whole blood will be collected at each time point specified in the list of study. Serum will 
be separated and kept frozen at –70°C until testing. 
Whole blood samples for cell-mediated immunity assays will be collected at each time 
point specified in the list of study procedures and kept at 20-25 °C until transfer to the 
immunogenicity laboratory for isolation of peripheral blood mononuclear cells (PBMC), 
freezing and storage until further testing.  Isolation of PBMCs needs to be performed 
within 4 hours after blood collection. 
5.5.2. Laboratory assays 
5.5.2.1. Screening and safety follow up 
Screening 
Tests will be performed to assay for HBV (HBsAg), HCV (total anti-HCV Ab) and HIV 
(anti-HIV1/2 Ab and p24 Ag) as well as for biochemistry, haematology and urinalysis 
[CBC - complete blood count which includes platelets, white blood cells, haematocrit and 
haemoglobin, BUN - Blood Urea Nitrogen, Creatinine, ALT -Alanine aminotransferase, 
AST - Aspartate Aminotransferase, Total bilirubin, alkaline phosphatases, urinalysis 
(proteins, RBC, leucocytes, glucose)]. A pregnancy test will also be performed on all 
females. 
Safety 
Tests will be performed to assay for CBC, BUN, creatinine, ALT, AST, total bilirubin, 
alc. phosph. and urinalysis (proteins, leucocytes, RBC, glucose) at the following time 
points : Days 0, 2, 7, 28, 56, 90, 150 and 210. 
M. tuberculosis cultures will be made from the injection site, i.d. the deltoid region of the 
non dominant arm, the urine and the stools separately from visit 4 and on, till two 
successive 4 week cultures are negative. Practically it means that cultures from each site 
will be done from V4 to V6. The cultures on visit V7 and after will depend on the result 
of the previous cultures. 
Cellular and humoral immunogenicity 
The techniques that will be used to analyse “the immune response” to the vaccine could 
in the future be updated to the best available approved procedure. 
Cellular and humoral immunogenicity 
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A. PBMCs and/or whole blood will be used to evaluate secondary outcomes and will 
involve: 
 The cell-mediated immune (CMI) response induced by the candidate vaccine 
MTBVAC as determined by ELISPOT on peripheral blood mononuclear cells 
(PBMC): frequency of IFNγ positive mononuclear cells in response to vaccine 
(ESAT-6, CFP10, PPD, whole BCG and whole MTBVAC) at screening, and at 
days 28, 210 in all cohorts 
 The cell-mediated immune (CMI) response induced by the candidate vaccine 
MTBVAC as determined by Intracellular Cell Staining (ICS): frequency of 
positive mononuclear cells for IL-2, TNFα and IFNγ in response to whole BCG 
and whole MTBVAC (overnight stimulation of whole blood or PBMC) at Day 
0, 28, 90, 210 in all cohorts. 
B. PBMCs and/or whole blood will be used to evaluate exploratory outcomes and will 
involve: 
o The cell-mediated immune (CMI) response induced by the candidate vaccine 
MTBVAC as determined by Intracellular Cell Staining (ICS): frequency of 
positive mononuclear cells expressing markers for memory, effector and 
regulatory subsets in response to live BCG and live MTBVAC at Day 0, 28, 90, 
210 in all cohorts on whole blood. 
o The cell-mediated immune (CMI) response induced by the candidate vaccine 
MTBVAC as determined by cytokine secretion into supernatant (Luminex 
assay) of IL-2, IFNγ, TNFα, IL-5, IL-13, GMCSF, IL-10, TGFβ, IL-17, IL-22 in 
response to live BCG and live MTBVAC (overnight culture) as well as against 
selected MTB antigens (long-term stimulation) on PBMCs at Day 0, 28, 90, 210 
in all cohorts. 
C. The humoral immune response induced by the candidate vaccine MTBVAC as 
measured by ELISA against selected MTB antigens, PPD, BCG and MTBVAC at 
Day 0, 28, 56, 90, 210 in all cohorts. 
D. The transcriptomic analysis of the immune response to the candidate vaccine 
MTBVAC at Day -30, -3, 0, 2, 7, 28, 56, 90, 150, 210 in all cohorts (refer to Table 1) 
5.5.3. Serology and CMI plan 
Serology and CMI plan will be performed according to plan detailed in Table 1. 
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6. INVESTIGATIONAL PRODUCT AND ADMINISTRATION 
6.1. MTBVAC vaccine  
The MTBVAC vaccine has been released by BIOFABRI, Porriño, Spain.  
The Quality Control Standards and Requirements for the candidate vaccine are described 
in separate release protocols and the required approvals have been obtained.  
All MTBVAC vials should be stored at +2°C to +8°C. 
Table 3 Composition of MTBVAC study vaccine and BCG control 
Vaccine 
Formulation 
(approximately per  
standard dose) 
Presentation Volume 
MTBVAC 
 
3 – 17 x 105 cfu 
 
Sucrose 16.5 mg 
 
Sodium glutamate 1.3 mg 
 
lyophilised pellet 
 in  vials (10 doses) 
 
0.1 mL/dosea 
BCG To be provided To be provided To be provided 
aAfter reconstitution with sterilised water for injections 
 
6.2. Dosage and administration 
Subjects will be administered one dose of the study vaccine or BCG control according to 
vaccination schedule. The vaccine dose will be administered intradermally in the non 
dominant arm at the deltoid level. A plain plaster (breathable) will be used to cover the 
site of injection. The plaster will be changed at the first visit, day 2 post-vaccination, and 
removed at second visit on day 7, provided there are no signs of leakage upon 
examination by medical practitioner. Subjects will be instructed to protect the plaster and 
site of vaccination from water. Volunteers will be provided with a waterproof shoulder 
sleeve that can be used in the shower to protect the vaccination site from getting wet. In 
the event that the plaster became loose or at risk of falling off, volunteers will be 
provided with a plastic sample bag and a spare plaster with clear instructions on how to 
replace the plaster and retain the used plaster in the provided plastic bag and return it to 
clinic for destruction (refer to Risk Documents for further details). 
6.2.1. Reconstitution of MTBVAC 
Prefilled syringes will be prepared by the CHUV pharmacy according to the 
randomization protocol and the following procedure for the different doses. 
1. Materials 
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1.1 MTBVAC, freeze dried vials, 5 x 106 cfu/vial 
1.2 MTBVAC diluent vials, sterile water for injection 
1.3 MTBVAC excipient solution vials (4.5 mL) 
 
 
2. Cohort 1- Dose 5 x 103 cfu/0.1 mL 
2.1 - Use MTBVAC diluent (sterile water for injection) for reconstitution of 
MTBVAC freeze dried vial. 
2.2 –  The rubber stopper must not be wiped with any antiseptic or detergent. If 
alcohol is used to swab the rubber stopper of the vial, it must be allowed to 
evaporate before the stopper is penetrated with the syringe needle. 
2.3 –  Using a sterile needle and syringe, transfer to the MTBVAC freeze dried 
vial 1 mL of MTBVAC diluent (sterile water for injections). Carefully 
invert the vial a few times to resuspend the lyophilised MTBVAC 
completely. Do not shake. 
2.4 –  Prepare MTBVAC vaccine dilution 1/10: Draw up into a sterile syringe 
0.5 mL of the vaccine suspension and transfer into a vial of MTBVAC 
sterile excipient solution (content 4.5 mL). Carefully invert the vial a few 
times to obtain a homogeneous vaccine suspension. Do not shake.  
2.5 – Dose 5 x 103 cfu/0.1 mL preparation(MTBVAC vaccine dilution 1/100): 
Drawn up into a sterile syringe 0.5 mL of the MTBVAC vaccine 1/10 
dilution and transfer into a vial of MTBVAC sterile excipients solution 
(content 4.5 mL). Carefully invert the vial a few times to obtain a 
homogeneous vaccine suspension. Do not shake. Each vial of 5 mL 
contains 50 doses of 5 x 103 cfu/0.1 mL. 
2.6 -  MTBVAC vaccine should be administered with a syringe fitted with a 
short bevel needle (gauge 25 or 26 G). 
2.7 –  The reconstituted vaccine should be used within 4 hours (storage at +2°- 
+8°C). 
 
 3. Cohort 2 - Dose 5 x 104 cfu/0.1 mL 
3.1 -  Use MTBVAC diluent (sterile water for injections) for reconstitution of 
MTBVAC freeze dried vial. 
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3.2 –  The rubber stopper must not be wiped with any antiseptic or detergent. If 
alcohol is used to swab the rubber stopper of the vial, it must be allowed to 
evaporate before the stopper is penetrated with the syringe needle. 
3.3 –  Using a sterile needle and syringe, transfer to the MTBVAC freeze dried 
vial 1 mL of MTBVAC diluent (sterile water for injections). Carefully 
invert the vial a few times to resuspend the lyophilised MTBVAC 
completely. Do not shake. 
3.4 –  Dose 5 x 104 cfu/0.1 mL preparation (MTBVAC vaccine dilution 1/10): 
Draw up into a sterile syringe 0.5 mL of the vaccine suspension and 
transfer into a vial of MTBVAC sterile excipient solution (content 4.5 
mL). Carefully invert the vial a few times to obtain a homogeneous 
vaccine suspension. Do not shake. Each vial of 5 mL contains 50 doses of 
5 x 104 cfu/0.1 mL. 
3.5 -  MTBVAC vaccine should be administered with a syringe fitted with a 
short bevel needle (gauge 25 or 26 G). 
3.6 –  The reconstituted vaccine should be used within 4 hours (storage at +2°- 
+8°C). 
 
4. Cohort 3 - Dose 5 x 105 cfu /0.1 mL 
4.1 -  Use MTBVAC diluent (sterile water for injections) for reconstitution of 
MTBVAC freeze dried vial. 
4.2 –  The rubber stopper must not be wiped with any antiseptic or detergent. If 
alcohol is used to swab the rubber stopper of the vial, it must be allowed to 
evaporate before the stopper is penetrated with the syringe needle. 
4.3 –  Using a sterile needle and syringe, transfer to the MTBVAC freeze dried 
vial 1 mL of MTBVAC diluent (sterile water for injections). Carefully 
invert the vial a few times to resuspend the lyophilised MTBVAC 
completely. Do not shake. Each vial of 1 mL contains 10 doses of 5 x 105 
cfu/0.1 mL. 
4.4 -  MTBVAC vaccine should be administered with a syringe fitted with a 
short bevel needle (gauge 25 or 26 G). 
4.5 –  The reconstituted vaccine should be used within 4 hours (storage at +2°- 
+8°C). 
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6.2.2. Reconstitution of BCG control 
Prefilled syringes will be prepared by the CHUV pharmacy according to randomization 
protocol using manufacturer´s diluent and following the manufacturer recommendations 
 
6.2.3. Administration of the MTBVAC Vaccine or BCG control 
Each 0.1 ml dose of the MTBVAC or the control BCG vaccines should be administered 
by intradermal injection above the deltoid muscle within 4 hours (storage at +2°- +8°C). 
The vaccinees will be observed closely for at least 60 minutes following the 
administration of vaccines, with appropriate medical treatment readily available in case 
of a rare anaphylactic reaction following the administration of vaccines. 
The vaccines will be administered at the Vaccination and Immunotherapy Center (VIC), 
CHUV, under the supervision of physicians skilled in the management of anaphylactic 
reactions.  
6.3. Storage 
All vaccines must be stored in a safe and locked place with no access for unauthorized 
personnel (CHUV Pharmacy). They must be kept in the refrigerator (+2°C to +8°C). 
Storage temperature should be monitored and documented at least once per day, using a 
calibrated min-max thermometer. It is advisable to have a back-up refrigerator/ freezer in 
case of power failure/ breakdown. Procedures must be in place to ensure that the vaccines 
are kept at the indicated temperature range at all times. 
The study monitor must be contacted, as soon as possible, if the cold chain is broken (e.g. 
vaccines become frozen or refrigeration fails). 
Storage conditions for transport of vaccines from country medical department or dispatch 
centre to study sites or between sites are described in Appendix C. 
 
6.4. Treatment allocation and randomization 
Subjects within each cohort will be assigned to one of 2 groups (vaccine or control) in the 
order in which they are enrolled into the study in a 3:1 manner. 
The treatment allocation at the investigator site will be performed by the CHUV 
Pharmacy.  
The person in charge of preparing the vaccination (Mrs Beatrice Pellet, CHUV 
Pharmacy) will have access the randomization program. Upon providing a subject 
number the randomization system will use the minimization algorithm to determine the 
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treatment number to be used for the subject. Note that as soon as the target number of 
subjects in a specific group has been reached, the enrolment will be frozen for this group. 
6.5. Method of blinding and breaking the study blind 
Data pertaining to the MTBVAC vaccine and to BCG control will be collected in an 
observer blinded manner. By observer blinded, we mean that during the course of the 
study the vaccine recipient and those responsible for the evaluation of safety and 
reactogenicity study parameters, will all be unaware of which vaccine preparation was 
administered to a particular volunteer. To do so, the MTBVAC vaccine and the BCG 
control will be prepared and blinded by the pharmacist whereas the vaccination will be 
done by the medical team (the co-investigator and/or the study nurse). The principal 
investigator and/or the co-investigator will be responsible for assessing safety and post-
vaccination side effects. Blinding will be maintained throughout the vaccination and 
follow-up portions of the vaccine trial.  
The CHUV Pharmacy is in charge of the randomisation process. A set of sealed 
envelopes with individual randomisation code will be sent to the VIC where they will 
always be available to the investigators. The code will be broken either by the CHUV 
Pharmacist (Mrs Pellet, Study Contact for Emergency Code Break) or by the 
investigators directly only in the case of medical events that the investigator/physician in 
charge of the subject feels cannot be treated without knowing the identity of the study 
vaccine(s). Another set will be held at Biofabri’s Headquarters as a backup. No code will 
be broken without the authorisation of the PI. The DSMB will be immediately informed 
by the PI. 
Biofabri’ policy (incorporating ICH E2A guidance, EU Clinical Trial Directive and 
Federal Regulations) is to unblind any serious adverse event (SAE) report associated with 
the use of the investigational product, which is unexpected and attributable/suspected, 
prior to regulatory reporting. The CHUV Pharmacist (Mrs Pellet is responsible for 
unblinding the treatment assignment in accordance with specified time frames for 
expedited reporting of SAEs (Refer to Section 8.7) 
The statistician who will perform the analysis will have access to the randomisation 
codes at the time of analysis and will be able to break the codes to perform the analysis. 
6.6. Replacement of unusable vaccine doses 
Additional vaccine doses will be provided to replace those that are unusable (see  
Appendix C for details of supplies). 
In addition to the vaccine doses provided for the planned number of subjects, at least 
100% additional doses will be supplied. In case a vaccine dose is broken or unusable, the 
investigator should replace it with a replacement vaccine dose. Although the sponsor 
need not be notified immediately in these cases (except in the case of cold-chain failure), 
documentation of the use of the replacement vaccine must be recorded by the investigator 
on the vaccine administration page of the CRF and on the vaccine accountability form. 
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The investigator will access the randomization register via the CHUV Pharmacy to obtain 
the replacement vial number. The system will ensure, in a blinded manner, that the 
replacement vial is of the same formulation as the randomized vaccine. 
6.7. Packaging 
See Appendix C for details  
6.8. Vaccine accountability 
See Appendix C. 
6.9. Concomitant medication/treatment 
At each study visit/contact, the investigator should question the subject about any 
medication(s) taken. 
All concomitant medications, with the exception of vitamins and/or dietary supplements, 
administered at ANY time during the period starting with administration of the study 
vaccine/control and ending at D210 of the follow up period are to be recorded with 
generic name of the medication (trade names are allowed for combination drugs, i.e. 
multi-component drugs), medical indication, total daily dose, route of administration, 
start and end dates of treatment. 
Any treatments and/or medications specifically contraindicated, e.g. any 
immunoglobulins, antibiotic, other blood products and any immune modifying drugs 
administered within three months preceding the vaccine administration or at any time 
during the study period are to be recorded with generic name of the medication (trade 
names are allowed for combination drugs only), medical indication, total daily dose, 
route of administration, start and end dates of treatment. Refer to Sections 4.3  and 4.4 . 
Any vaccine not foreseen in the study protocol administered in the period beginning 30 
days preceding administration of study vaccine/control and ending two months after 
administration of study vaccine/control is to be recorded with trade name, route of 
administration and date(s) of administration. Refer to Sections 4.3  and 4.4. 
A prophylactic medication is a medication administered in the absence of ANY symptom 
and in anticipation of a reaction to the vaccination (e.g. an anti-pyretic is considered to be 
prophylactic when it is given in the absence of fever [axillary temperature < 37.5°C] and 
any other symptom, to prevent fever from occurring). Any concomitant medication 
administered prophylactically in anticipation of reaction to the vaccination must be 
recorded in the CRF with generic name of the medication (trade names are allowed for 
combination drugs only), total daily dose, route of administration, start and end dates of 
treatment and coded as ‘Prophylactic’. 
Concomitant medication administered for the treatment of an AE or SAE within the 
follow-up period for adverse events must be recorded in the CRF with generic name of 
the medication (trade names are allowed for combination drugs only), medical indication 
Version V104 21-03-2013 52 
 
 MTBVAC Clinical Trial Protocol  
 
 
(including which AE/SAE), total daily dose, route of administration, start and end dates 
of treatment. Refer to Section 8.2 for definition of SAE. 
 
7. HEALTH ECONOMICS 
Not applicable.  
 
8. ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an adverse event (AE) or serious adverse event (SAE) as 
provided in this protocol. During the study, when there is a safety evaluation, the 
investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in 
this section of the protocol.  
Each subject will be instructed to contact the investigator immediately should they 
manifest any signs or symptoms they perceive as serious. 
8.1. Definition of an adverse event 
An AE is any untoward medical occurrence in a clinical investigation subject, temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product.  
Examples of an AE include: 
 Significant or unexpected worsening or exacerbation of the condition/indication 
under study. See Section 8.3 ‘Lack of Efficacy’ for additional information. 
 Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
 New conditions detected or diagnosed after investigational product administration 
even though it may have been present prior to the start of the study. 
 Signs, symptoms, or the clinical sequelae of a suspected interaction. 
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication (overdose per se should not be 
reported as an AE/SAE). 
 Signs, symptoms temporally associated with vaccine administration. 
Examples of an AE do not include: 
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 Medical or surgical procedure (e.g. endoscopy, appendectomy); the condition that 
leads to the procedure is an AE. 
 Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
 Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
 The disease/disorder being studied, or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
AEs may include pre- or post-treatment events that occur as a result of protocol-
mandated procedures (i.e. invasive procedures, modification of subject’s previous 
therapeutic regimen). 
N.B. AEs to be recorded as endpoints (solicited events) are described in Section 8.5.1. 
All other AEs will be recorded as UNSOLICITED AES. 
Example of events to be recorded in the medical history section of the CRF: 
 Pre-existing conditions or signs and/or symptoms present in a subject prior to the start 
of the study (i.e. prior to the first study procedure) should be recorded in the medical 
history section of the subject’s CRF. 
 
8.2. Definition of a serious adverse event  
A serious adverse event (SAE) is any untoward medical occurrence that: 
a results in death, 
b is life-threatening, 
NOTE: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in 
which the subject was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe. 
c requires hospitalization or prolongation of existing hospitalization, 
NOTE: In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or out-
patient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfils any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
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d results in disability/incapacity, or 
NOTE: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, 
diarrhoea, influenza, and accidental trauma (e.g. sprained ankle) which may interfere or 
prevent everyday life functions but do not constitute a substantial disruption. 
e is a congenital anomaly/birth defect in the offspring of a study subject. 
Medical or scientific judgement should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
subject or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These should also be considered serious. 
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalization. 
 
8.3. Definition of Suspected Unexpected Serious Adverse 
Reaction: 
Suspected Unexpected Serious Adverse Reaction (or SUSAR) are any unsolicited serious 
AE that are suspected to be linked to the administration of the investigational product. 
The investigator will report any fatal or life threatening SUSAR to the Local Ethical 
Committee and Swiss institute of the therapeutic products “Swissmedic” as soon as 
possible, but not later than 7 working days after the event occurred. In case of non life 
threatening SUSARs, the event will be reported in a 15 days period of time. The report 
will contain the full description of the event, the identification of the volunteer - 
including the two digits code, age and sex – and the details of the study product, meaning 
its posology, its route of administration, the beginning and the end of administration. The 
announcements of SUSAR to Swissmedic will be sent by post to: “Swissmedic, Institut 
suisse des produits thérapeutiques, Services d’inspection, Case Manager, section 
Transplants, Case postale, 3000 Berne 9” using the CIOMS form. If sent also per e-mail, 
the e-mail address should be to Julia.djonova@swissmedic.ch, using the CIOMS form. 
The CIOMS form has to be sent by post in any case. It should be noted that, if needed, 
the code will be break for security reason. 
Furthermore, the sponsor has to announce to Swissmedic as per Art 22, §4 OClin, all 
SAE with presumed causal link with the administered drug (i.e. SADR, serious adverse 
drug reactions) (http://www.swissmedic.ch/org/00064/00067/00336/00855/ 
index.html?lang=fr, I-315.AA.03-A4_01F Aide-mémoire: Obligation d’annoncer les 
effets indésirables lors d’essais cliniques avec des transplants standardisés). 
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8.4. Clinical laboratory parameters and other abnormal 
assessments qualifying as adverse events and serious adverse 
events 
Abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) or other 
abnormal assessments (e.g.X-rays, vital signs, etc.) that are judged by the investigator to 
be clinically significant will be recorded as AEs or SAEs if they meet the definition of an 
AE, as defined in Section 8.1 or SAE, as defined in Section 8.2 . Clinically significant 
abnormal laboratory findings or other abnormal assessments that are detected during the 
study or are present at baseline and significantly worsen following the start of the study 
will be reported as AEs or SAEs. However, clinically significant abnormal laboratory 
findings or other abnormal assessments that are associated with the disease being studied, 
unless judged by the investigator as more severe than expected for the subject’s 
condition, or that are present or detected at the start of the study and do not worsen, will 
not be reported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgement in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
8.5. Time period, frequency, and method of detecting adverse 
events and serious adverse events 
All AEs occurring during the 210 day follow up period following administration of study 
vaccine must be recorded on the Adverse Event form in the subject's CRF, irrespective of 
severity or whether or not they are considered vaccination-related. 
The standard time period for collecting and recording SAEs will begin at randomization 
or the first receipt of vaccine and will end 210 days following administration of the study 
vaccine/control for each subject. See Section 8.8 for instructions for reporting and 
recording SAEs. 
Additionally, in order to fulfil international reporting obligations, SAEs that are related to 
study participation (e.g. procedures, invasive tests, a change from existing therapy) or are 
related to a concurrent medication will be collected and recorded from the time the 
subject consents to participate in the study until she/he is discharged. 
The investigator will inquire about the occurrence of AEs/SAEs at every visit/contact 
during the study. 
All AEs either observed by the investigator or one of his clinical collaborators or reported 
by the subject spontaneously or in response to a direct question will be evaluated by the 
investigator. AEs not previously documented in the study will be recorded in the Adverse 
Event form within the subject's CRF. The nature of each event, date and time (where 
appropriate) of onset, outcome, intensity and relationship to vaccination should be 
established. Details of any corrective treatment should be recorded on the appropriate 
page of the CRF (Refer to Section 6.9). 
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As a consistent method of soliciting AEs, the subject should be asked a non-leading 
question such as: 
"Have you felt different in any way since receiving the vaccine or since the previous 
visit?" 
N.B. The investigator should record only those AEs having occurred within the time 
frame defined above. 
AEs already documented in the CRF, i.e. at a previous assessment, and designated as “not 
recovered/not resolved” or “recovering/resolving” should be reviewed at subsequent 
visits, as necessary. If these have resolved, the documentation in the CRF should be 
completed.  
N.B.  If an AE changes in frequency or intensity during the specified reporting period, a 
new record of the event will be entered. 
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE on the CRF or SAE Report Form as applicable. It is not acceptable for the 
investigator to send photocopies of the subject’s medical records to Biofabri in lieu of the 
appropriate completed AE/SAE pages. However, there may be instances when copies of 
medical records for certain cases are requested by Biofabri. In this instance, all subject 
identifiers will be blinded on the copies of the medical records prior to submission to 
Biofabri. 
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms. 
8.5.1. Solicited adverse events 
A 7-day follow-up (Day 0 to 6) of solicited local adverse events at each injection site will 
be performed after vaccination. Data concerning the following adverse events will be 
solicited using diary cards provided by the sponsor. 
Table 4 Solicited local adverse events 
Solicited local adverse events 
Pain at injection site 
Redness at injection site 
Swelling at injection site 
Pruritus at injection site 
Leakage at injection site 
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8.5.2. Solicited general AEs 
A 7-day follow-up (Day 0 to 6) of solicited general adverse events will be performed 
after vaccination. Data concerning the following adverse events will be solicited using 
diary cards provided by the sponsor. 
Table 5 Solicited general adverse events 
Solicited general adverse events 
Fatigue 
Fever 
Gastrointestinal symptoms* 
Headache 
Musculo-skeletal pains 
*Gastrointestinal symptoms include nausea, vomiting, diarrhea and/or abdominal pain. 
N.B. Temperature will be recorded in the evening. Should additional temperature 
measurements be performed at other times of day, the highest temperature will be 
recorded. 
8.6. Evaluating adverse events and serious adverse events 
8.6.1. Assessment of intensity 
Intensity of the following AEs will be assessed as described in Table 6. 
Table 6 Intensity scales for solicited symptoms 
Adverse Event Intensity grade Parameter 
Pain at injection site 0 Absent 
 1 Painful on touch 
 2 Painful when limb is moved 
 3 Pain that prevents normal activity 
Redness at injection site 0 None = 0 mm 
(Greatest diameter in mm) 1   0 < redness ≤20 mm 
 2 20 < redness ≤ 50 mm 
 3 > 50 mm 
Prurit at injection site 0 Normal 
(Greatest diameter in mm) 1 Easily tolerated 
 2 Interferes with normal activity 
 3 Prevents normal activity 
Swelling at injection site 0 None = 0 mm 
(Greatest diameter in mm) 1   0 < swelling ≤20 mm 
 2 20 < swelling ≤ 50 mm 
 3 > 50 mm 
Fluid leakage at injection site 0 None 
 1 Weak 
 2 Moderate 
 3 Strong 
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Adverse Event Intensity grade Parameter 
Fever* 0 < 37.5°C 
(Temperature in °C) 1 37,5 ≤ temperature < 38,0°C 
 2 38,0 ≤ temperature < 39,0°C 
 3 ≥ 39,0°C 
Headache 0 Normal 
 1 Easily tolerated 
 2 Interferes with normal activity 
 3 Prevents normal activity 
Fatigue 0 Normal 
 1 Easily tolerated 
 2 Interferes with normal activity 
 3 Prevents normal activity 
Gastrointestinal symptoms 0 Normal 
(nausea, vomiting, diarrhoea 1 Easily tolerated 
and/or abdominal pain) 2 Interfere with normal activity 
 3 Prevent normal activity 
Musculo-skelettal pains 0 Normal 
 1 Easily tolerated 
 2 Interfere with normal activity 
 3 Prevent normal activity 
*Fever is defined as axillary temperature ≥ 37.5 °C  
The investigator will make an assessment of intensity for all other AEs, i.e. unsolicited 
symptoms, including SAEs reported during the study. The assessment will be based on 
the investigator’s clinical judgement. The intensity of each AE and SAE recorded in the 
CRF or SAE Report Form, as applicable, should be assigned to one of the following 
categories: 
1 (mild) = An AE which is easily tolerated by the subject, causing minimal 
discomfort and not interfering with everyday activities. 
2 (moderate) = An AE which is sufficiently discomforting to interfere with normal 
everyday activities. 
3 (severe) = An AE which prevents normal, everyday activities. (In adults/ 
adolescents, such an AE would, for example, prevent attendance at work/ 
school and would necessitate the administration of corrective therapy.) 
An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 3 is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as 
Grade 3. An event is defined as ‘serious’ when it meets one of the pre-defined outcomes as 
described in Section 8.2. 
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8.6.2. Assessment of causality 
The investigator is obligated to assess the relationship between investigational product 
and the occurrence of each AE/SAE. The investigator will use clinical judgement to 
determine the relationship. Alternative causes, such as natural history of the underlying 
diseases, concomitant therapy, other risk factors and the temporal relationship of the 
event to the investigational product will be considered and investigated. The investigator 
will also consult the Investigator Brochure and/or Product Information, for marketed 
products, in the determination of his/her assessment. 
There may be situations when a SAE has occurred and the investigator has minimal 
information to include in the initial report to Biofabri. However, it is very important that 
the investigator always makes an assessment of causality for every event prior to 
transmission of the SAE Report Form to Biofabri. The investigator may change his/her 
opinion of causality in light of follow-up information, amending the SAE Report Form 
accordingly. The causality assessment is one of the criteria used when determining 
regulatory reporting requirements. 
All solicited local (injection site) reactions will be considered causally related to 
vaccination. Causality of all other AEs should be assessed by the investigator using the 
following question: 
Is there a reasonable possibility that the AE may have been caused by the investigational 
product? 
NO : The AE is not causally related to administration of the study vaccine/control. 
There are other, more likely causes and administration of the study 
vaccine/control is not suspected to have contributed to the AE. 
YES : There is a reasonable possibility that the vaccine contributed to the AE.  
Non-serious and serious AEs will be evaluated as two distinct events. If an event meets 
the criteria to be determined “serious” (see Section 8.2 for definition of serious adverse 
event), it will be examined by the investigator to the extent to be able to determine ALL 
contributing factors applicable to each serious adverse event. 
Other possible contributors include: 
 Medical history 
 Other medication 
 Protocol required procedure 
 Other procedure not required by the protocol 
 Lack of efficacy of the vaccine(s), if applicable 
 Erroneous administration 
 Other cause (specify). 
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8.6.3. Medically attended visits 
For each solicited and unsolicited symptom the subject experiences, the subject will be 
asked if he received medical attention defined as hospitalization, an emergency room 
visit or a visit to or from medical personnel (medical doctor) for any reason and this 
information will be recorded in the CRF. 
8.7. Follow-up of adverse events, serious adverse events/ 
Suspected Unexpected Serious Adverse Reaction (SUSAR) and 
assessment of outcome 
After the initial AE/SAE/SUSAR report, the investigator is required to proactively follow 
each subject and provide further information to Biofabri on the subject’s condition. 
All AEs and SAEs/SUSAR documented at a previous visit/contact and designated as not 
recovered/not resolved or recovering/resolving will be reviewed at subsequent 
visits/contacts. 
Investigators will follow-up subjects: 
 with SAEs/SUSARs or subjects withdrawn from the study as a result of an AE, until 
the event has resolved, subsided, stabilized, disappeared, the event is otherwise 
explained, or the subject is lost to follow-up;  
 or, in the case of other non-serious AEs, until they complete the study or they are lost 
to follow-up.  
Clinically significant laboratory abnormalities will be followed up until they have 
returned to normal, or a satisfactory explanation has been provided. Additional 
information (including but not limited to laboratory results) relative to the subsequent 
course of such an abnormality noted for any subject must be made available to the Study 
Medical Monitor. 
Biofabri may request that the investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations to elucidate as fully as possible the nature 
and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies 
during participation in the study or during a recognized follow-up period, Biofabri will be 
provided with a copy of any available post-mortem findings, including histopathology. 
New or updated information will be recorded on the originally completed SAE Report 
Form, with all changes signed and dated by the investigator. The updated SAE report 
form should be resent to Biofabri within 24 hours of receipt of the follow-up information 
as outlined in Section8.8.1. 
Outcome of any non-serious AE occurring within 210 days post-vaccination (i.e. 
unsolicited AE) as well as any SAE reported during the entire study will be assessed as: 
 Recovered/resolved 
 Not recovered/not resolved 
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 Recovering/resolving 
 Recovered with sequelae/resolved with sequelae 
 Fatal (SAEs only). 
 
8.8. Prompt reporting of serious adverse events to Biofabri 
8.8.1. Time frames for submitting serious adverse event reports to 
Biofabri 
SAEs/SUSARs will be reported promptly to BIOFABRI once the investigator determines 
that the event meets the protocol definition of an SAE/SUSARs. The investigator or 
designate will fax the SAE reports to Biofabri’ Study Contact for Serious Adverse Event 
Reporting WITHIN 24 HOURS OF HIS/HER BECOMING AWARE OF THESE EVENTS. Additional 
or follow-up information relating to the initial SAE report is also to be reported to the 
Biofabri’ Study Contact for Serious Adverse Event Reporting within 24 hours of receipt 
of such information. 
8.8.2. Completion and transmission of serious adverse event reports to 
Biofabri 
Once an investigator becomes aware that a SAE/SUSAR has occurred in a study subject, 
she/he will report the information to BIOFABRI within 24 hours as outlined in Section 
8.8.1. The SAE/SUSAR Report Form will always be completed as thoroughly as possible 
with all available details of the event, signed by the investigator (or designee), and 
forwarded to BIOFABRI within the designated time frames. If the investigator does not 
have all information regarding an SAE, he/she will not wait to receive additional 
information before notifying BIOFABRI of the event and completing the form. The form 
will be updated when additional information is received and forwarded to BIOFABRI 
WITHIN 24 HOURS as outlined in Section 8.8.1. 
The investigator will always provide an assessment of causality at the time of the initial 
report as described in Section 8.6.2. 
Facsimile (Fax) transmission of the SAE/SUSAR Report Form is the preferred method to 
transmit this information to the Study Contact for Reporting SAEs. In rare circumstances 
and in the absence of facsimile equipment, notification by telephone is acceptable, with a 
copy of the SAE Report Form sent by overnight mail. Initial notification via the 
telephone does not replace the need for the investigator to complete and sign the 
SAE/SUSAR Report Form within 24 hours as outlined in Section 8.8.1. 
In the event of a death determined by the investigator to be related to vaccination, 
sending of the fax must be accompanied by telephone call to the Study Contact for 
Reporting SAEs/SUSARs. 
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Primary Study contacts at Biofabri 
Clinical Development Manager and Local BIOFABRI Contact person 
 
Dr Juana DOCE 
BIOFABRI, S.L. 
La Relva s/n, 36400 Porriño – Pontevedra. SPAIN 
 
Email: j.doce@biofabri.es  
Tel. office: + 34 986 34 52 16 
Fax:           + 34 986 34 52 01   
Biofabri Clinical and Regulatory Affairs Monitor 
 
Dr. Luc HESSEL 
Chair of the Clinical Development team of TBVI 
Tuberculosis Vaccine Initiative (TBVI) 
Runderweg 6, 8219 Pk Lelystad. THE NETHERLANDS 
 
Email: luc.hessel@orange.fr 
Tel: +31 320 277 550 
 
Study Contact at Biofabri for Reporting Serious Adverse Events 
 
Dr Eugenia PUENTES 
BIOFABRI, S.L.   
La Relva s/n, 36400 Porriño (Pontevedra), SPAIN  
 
Email : e.puentes@biofabri.es  
Tel. office: +34 986 34 52 13   
Fax: :+34 986 34 52 01 
 
  
8.9. Regulatory reporting requirements for serious adverse 
events 
The investigator will promptly report all SAEs/SUSARs to BIOFABRI in accordance 
with the procedures detailed in Section8.8. Biofabri has a legal responsibility to promptly 
notify, as appropriate, both the local regulatory authorities and other regulatory agencies 
about the safety of a product under clinical investigation. Prompt notification of 
SAEs/SUSARs by the investigator to the Study Contact for Reporting SAEs is essential 
so that legal obligations and ethical responsibilities towards the safety of other subjects 
are met. 
The investigator, or responsible person according to local requirements, will comply with 
the applicable local regulatory requirements related to the reporting of SAEs/SUSARs to 
the IRB/IEC and, if required, to the applicable government authority. 
Investigator safety reports are prepared according to BIOFABRI policy and are 
forwarded to investigators as necessary.  An investigator safety report is prepared for a 
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SAE(s) that is both attributable to investigational product and unexpected.  The purpose 
of the report is to fulfil specific regulatory and Good Clinical Practice (GCP) 
requirements, regarding the product under investigation. 
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safety information (e.g., summary or listing of SAEs) from Biofabri will file it 
with the Investigator Brochure or other appropriate study documentation and will notify 
the IRB or IEC, if appropriate according to local requirements 
8.10. Post study adverse events and serious adverse events 
A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
detection period defined in Section 8.5. Investigators are not obligated to actively seek 
AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a death, at any time after a 
subject has been discharged from the study, and he/she considers the event reasonably 
related to the investigational product, the investigator will promptly notify the Study 
Contact for Reporting SAEs. 
8.11. Pregnancy 
Subjects who become pregnant during the study must not receive additional doses of 
study vaccine/ control but may continue other study procedures at the discretion of the 
investigator. The subject will not have blood drawn or chest X-rays, as normally 
mandated by the protocol. However, pregnant subjects will undergo all other evaluations 
according to Protocol. 
The investigator, or his/her designee, will collect pregnancy information on any subject 
who becomes pregnant while participating in this study. The investigator, or his/her 
designee, will record pregnancy information on the Pregnancy Report Form provided by 
the Sponsor and submit it to BIOFABRI within 24 hours of learning of a subject's 
pregnancy. The subject will be followed to determine the outcome of the pregnancy. At 
the end of the pregnancy, whether that be full-term or prematurely, information on the 
status of the mother and child will be forwarded to BIOFABRI. Generally, follow-up will 
be no longer than six to eight weeks following the estimated delivery date. 
While pregnancy itself is not considered an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be recorded as an AE or a 
SAE, as described in Section 8.1 and 8.2, and will be followed as described in Section 
8.6. 
A spontaneous abortion is always considered to be a SAE and will be reported as 
described in Section 8.8. Furthermore, any SAE occurring as a result of a post-study 
pregnancy AND considered reasonably related in time to receipt of the investigational 
product by the investigator, will be reported to Biofabri as described in Section 8.10. 
While the investigator is not obligated to actively seek this information from former 
study participants, he/she may learn of a pregnancy through spontaneous reporting. 
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Information on pregnancies identified during the screening phase/prior to vaccine 
administration does not need to be collected; this information need not be communicated 
to safety. 
8.12. Treatment of adverse events 
Treatment of any adverse event is at the sole discretion of the investigator and according 
to current good medical practice. Any medication administered for the treatment of an 
AE should be recorded in the subject’s CRF. Refer to Section 6.9. 
 
9. SUBJECT COMPLETION AND WITHDRAWAL 
9.1. Subject completion 
A subject, who returns for the concluding visit and/or is available for the concluding 
contact foreseen in the protocol, is considered to have completed the study. 
9.2. Subject withdrawal 
Subjects who are withdrawn for AEs must be clearly distinguished from subjects who are 
withdrawn for other reasons. Investigators will follow subjects who are withdrawn as 
result of a SAE/SUSAR/AE until resolution of the event (see Section 8.6). 
9.2.1. Subject withdrawal from the study 
From an analysis perspective, a ‘withdrawal’ from the study is any subject who did not 
come back for the concluding visit/was not available for the concluding contact foreseen 
in the protocol.  
A subject qualifies as a ‘withdrawal’ from the study when no study procedure has 
occurred, no follow-up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact. 
Investigators will make an attempt to contact those subjects who do not return for 
scheduled visits or follow-up.  
Information relative to the withdrawal will be documented on the Study Conclusion page 
of the CRF. The investigator will document whether the decision to withdraw from the 
study was made by the subject or the investigator and which of the following possible 
reasons was responsible for withdrawal: 
 serious adverse event 
 non-serious adverse event 
 protocol violation (specify) 
 consent withdrawal, not due to an adverse event 
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 moved from the study area 
 lost to follow-up 
 other (specify) 
 
9.3. Screen and baseline failures 
Screening evaluations (see section 0) will occur within 60 days prior to Day 0. Informed 
consent will be collected from patients willing to participate in the study prior to any 
study procedure. No study-specific invasive procedures may be performed before 
informed consent is signed.  
Upon completion of all screening procedures, the investigator, or designee, will review 
the inclusion/exclusion criteria for each subject and will verify that all eligibility criteria 
are met. Subjects that meet all inclusion/exclusion criteria will be scheduled for their 
baseline (Day 0) visit. Their screening information will be recorded on the appropriate 
case report form (CRF). 
 
10. DATA EVALUATION: CRITERIA FOR EVALUATION OF 
OBJECTIVES 
10.1. Primary endpoints 
Safety and reactogenicity for all subjects as determined by: 
 Occurrence of solicited symptoms during the 7-day follow-up period following 
vaccination (day of vaccination and 6 subsequent days). 
 Occurrence of unsolicited symptoms during the 210-day follow-up period following 
vaccination (day of vaccination and 209 subsequent days).  
 Occurrence of grade 3 vaccine related local and general symptoms during the 210-day 
follow-up period following vaccination (day of vaccination and 209 subsequent 
days). 
 Occurrence of serious adverse events throughout the entire study period. 
10.2. Secondary endpoints 
Immunogenicity assessment for all subjects as determined by:   
 The cell-mediated immune (CMI) response induced by the candidate vaccine 
MTBVAC as determined by ELISPOT on peripheral blood mononuclear cells 
(PBMC): frequency of IFNγ positive mononuclear cells in response to vaccine 
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(ESAT-6, CFP10, PPD, live BCG and live MTBVAC) at screening, and at days 28, 
210 in all cohorts 
 The cell-mediated immune (CMI) response induced by the candidate vaccine 
MTBVAC as determined by Intracellular Cell Staining (ICS): frequency of positive 
mononuclear cells for IL-2, TNFα and IFNγ in response to live BCG and live 
MTBVAC (overnight stimulation) at Day 0, 28, 90, 210 in all cohorts on whole 
blood. 
10.3. Immunogenicity assessment for all subjects as determined 
by estimated sample size  
The sample size of 9 subjects per group is based on what is typical and reasonable for a 
Phase 1 study, and not on statistical consideration of power to observe differences 
between the cohorts. The sample size will allow Biofabri’ to define an initial safety 
profile for MTBVAC vaccination and to perform an evaluation of immunogenicity 
specific to MTBVAC.  
The number of volunteers in the study should give important clues suggesting large 
differences in the rate of adverse reactions or immunogenicity between the vaccine 
candidate and the control within each cohort. 
10.4. Study cohorts to be evaluated 
10.4.1. Total Vaccinated cohort 
The Total Vaccinated cohort will include all vaccinated subjects for whom data are 
available. Thus, the Total analysis of safety will include all vaccinated subjects and the 
Total analysis of immunogenicity/efficacy will include vaccinated subjects for whom 
data concerning immunogenicity/efficacy endpoint measures are available.  
10.4.2. According To Protocol (ATP) cohort for analysis of 
immunogenicity 
The ATP cohort for analysis of immunogenicity will include all evaluable subjects (i.e. 
those meeting all eligibility criteria, complying with the procedures defined in the 
protocol, with no elimination criteria during the study) for whom data concerning 
immunogenicity endpoint measures are available. 
10.5. Derived and transformed data 
For a given subject and a given immunogenicity measurement, missing or non-evaluable 
measurements will not be replaced. Therefore, an analysis will exclude subjects with 
missing or non-evaluable measurements. 
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• For intracellular cytokine staining, the results will be expressed as the number of 
antigen-specific cytokine-producing cells per million CD4+ T cells or CD8+ T cells 
after subtraction of background activity. 
Subjects who missed reporting symptoms (solicited/unsolicited or concomitant 
medications) will be treated as subjects without symptoms (solicited/unsolicited or 
concomitant medications, respectively). 
In case of significant non-compliance of study procedures for reporting symptoms, the 
analysis plan will be reassessed to ensure more accurate reporting of study data by further 
analysis. 
10.6. Final analyses 
The final report will include data on safety/reactogenicity and available CMI data 
collected during the pre-vaccination up until 7 months post-vaccination. Data will be 
from a cleaned database. 
10.6.1. Analysis of demographics/baseline characteristics 
Demographic characteristics (age, gender, race) of each study cohort will be tabulated. 
The mean age (plus range and standard deviation) by gender of the enrolled subjects, as a 
whole, and per group, will be calculated. 
The distribution of subjects enrolled will be tabulated as a whole and per group. 
10.6.2. Analysis of immunogenicity 
The primary analysis will be based on the ATP cohort for analysis of immunogenicity. 
An analysis on the Total Vaccinated cohort will be performed only if more than 10% of 
the subjects are excluded from the ATP cohort for analysis of immunogenicity. 
10.6.2.1. Intracellular cytokine staining data 
The frequency of specific CD4+ T cells and CD8+ T cells secreting cytokines will be 
summarised for each vaccination group, at each time point (descriptive statistics).  
10.6.3. Analysis of safety 
The primary analysis will be based on the Total Vaccinated cohort. 
The percentage of subjects with at least one local adverse event (solicited and 
unsolicited), with at least one general adverse event (solicited and unsolicited) and with 
any adverse event during the solicited follow-up period will be tabulated with exact 95% 
CI overall.  
The percentage of subjects reporting each individual solicited local and general adverse 
event during the solicited follow-up period will be tabulated with exact 95% CI. 
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Occurrence of fever and related fever will be reported per 0.5°C cumulative increments. 
Duration and prevalence of fever will be presented. 
For all solicited symptoms, the same tabulation will be performed for grade 3 adverse 
events and for adverse events with relationship to vaccination. 
The proportion of subjects with at least one report of unsolicited adverse event classified 
by the World Health Organization Preferred Terms or by the Medical Dictionary for 
Regulatory Activities (MedDRA), whenever available, and reported up to 210 days after 
vaccination will be tabulated with exact 95% CI. The same tabulation will be performed 
for grade 3 unsolicited adverse events and for unsolicited adverse events with a 
relationship to vaccination. 
Serious adverse events will be described in detail. 
The proportion of AEs resulting in a medically attended visit will also be tabulated. 
10.7. Planned interim analysis 
No interim analyses of data are planned. 
 
11. ADMINISTRATIVE MATTERS 
To comply with Good Clinical Practice important administrative obligations relating to 
investigator responsibilities, monitoring, archiving data, audits, confidentiality and 
publications must be fulfilled. See Appendix B for details. 
  
Version V104 21-03-2013 69 
 
 MTBVAC Clinical Trial Protocol  
 
 
12. REFERENCES 
Camacho, L. R., D. Ensergueix, et al. (1999). "Identification of a virulence gene cluster 
of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis." 
Mol Microbiol 34(2): 257-267. 
 
Cox, J. S., B. Chen, et al. (1999). "Complex lipid determines tissue-specific replication of 
Mycobacterium tuberculosis in mice." Nature 402(6757): 79-83. 
 
Horwitz, M. A. and G. Harth (2003). "A new vaccine against tuberculosis affords greater 
survival after challenge than the current vaccine in the guinea pig model of 
pulmonary tuberculosis." Infect Immun 71(4): 1672-1679. 
 
Kamath, A. T., U. Fruth, et al. (2005). "New live mycobacterial vaccines: the Geneva 
consensus on essential steps towards clinical development." Vaccine 23(29): 
3753-3761. 
 
Nambiar, J. K., R. Pinto, et al. "Protective immunity afforded by attenuated, PhoP-
deficient Mycobacterium tuberculosis is associated with sustained generation of 
CD4(+) T-cell memory." Eur J Immunol 42(2): 385-392. 
 
Skeiky, Y. A. and J. C. Sadoff (2006). "Advances in tuberculosis vaccine strategies." Nat 
Rev Microbiol 4(6): 469-476. 
 
Trunz, B. B., P. Fine, et al. (2006). "Effect of BCG vaccination on childhood tuberculous 
meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of 
cost-effectiveness." Lancet 367(9517): 1173-1180. 
 
Walker, K. B., M. J. Brennan, et al. "The second Geneva Consensus: Recommendations 
for novel live TB vaccines." Vaccine 28(11): 2259-2270. 
 
Young, D. and C. Dye (2006). "The development and impact of tuberculosis vaccines." 
Cell 124(4): 683-687. 
 
 
  
Version V104 21-03-2013 70 
 
 MTBVAC Clinical Trial Protocol  
 
 
13. APPENDIX A : 
WORLD MEDICAL ASSOCIATION DECLARATION OF 
HELSINKI 
Recommendations guiding physicians 
in biomedical research involving human subjects 
Adopted by the 18th World Medical Assembly 
Helsinki, Finland, June 1964 
and amended by the  
29th World Medical Assembly 
Tokyo, Japan, October 1975 
35th World Medical Assembly 
Venice, Italy, October 1983 
41st World Medical Assembly 
Hong Kong, September 1989 
and the 
48th General Assembly 
Somerset West, Republic of South Africa, October 1996 
INTRODUCTION 
It is the mission of the physician to safeguard the health of the people. His or her 
knowledge and conscience are dedicated to the fulfilment of this mission. 
The Declaration of Geneva of the World Medical Association binds the physician with 
the words, "The health of my patient will be my first consideration," and the International 
Code of Medical Ethics declares that, "A physician shall act only in the patient's interest 
when providing medical care which might have the effect of weakening the physical and 
mental condition of the patient." 
The purpose of biomedical research involving human subjects must be to improve 
diagnostic, therapeutic and prophylactic procedures and the understanding of the etiology 
and pathogenesis of disease. 
In current medical practice most diagnostic, therapeutic or prophylactic procedures 
involve hazards. This applies especially to biomedical research. 
Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
In the field of biomedical research a fundamental distinction must be recognized between 
medical research in which the aim is essentially diagnostic or therapeutic for a patient, 
and medical research, the essential object of which is purely scientific and without 
implying direct diagnostic or therapeutic value to the person subjected to the research. 
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Special caution must be exercised in the conduct of research which may affect the 
environment, and the welfare of animals used for research must be respected. 
Because it is essential that the results of laboratory experiments be applied to human 
beings to further scientific knowledge and to help suffering humanity, the World Medical 
Association has prepared the following recommendations as a guide to every physician in 
biomedical research involving human subjects. They should be kept under review in the 
future. It must be stressed that the standards as drafted are only a guide to physicians all 
over the world. Physicians are not relieved from criminal, civil and ethical 
responsibilities under the laws of their own countries. 
I. BASIC PRINCIPLES  
1. Biomedical research involving human subjects must conform to generally accepted 
scientific principles and should be based on adequately performed laboratory and 
animal experimentation and on a thorough knowledge of the scientific literature. 
2. The design and performance of each experimental procedure involving human 
subjects should be clearly formulated in an experimental protocol which should be 
transmitted for consideration, comment and guidance to a specially appointed 
committee independent of the investigator and the sponsor provided that this 
independent committee is in conformity with the laws and regulations of the country 
in which the research experiment is performed. 
3. Biomedical research involving human subjects should be conducted only by 
scientifically qualified persons and under the supervision of a clinically competent 
medical person. The responsibility for the human subject must always rest with a 
medically qualified person and never rest on the subject of research, even though the 
subject has given his or her consent. 
4. Biomedical research involving human subjects cannot legitimately be carried out 
unless the importance of the objective is in proportion to the inherent risk to the 
subject. 
5. Every biomedical research project involving human subjects should be preceded by 
careful assessment of predictable risks in comparison with foreseeable benefits to the 
subject or to others. Concern for the interests of the subject must always prevail over 
the interests of science and society. 
6. The right of the research subject to safeguard his or her integrity must always be 
respected. Every precaution should be taken to respect the privacy of the subject and 
to minimize the impact of the study on the subject's physical and mental integrity and 
on the personality of the subject. 
7. Physicians should abstain from engaging in research projects involving human 
subjects unless they are satisfied that the hazards involved are believed to be 
predictable. Physicians should cease any investigation if the hazards are found to 
outweigh the potential benefits. 
8. In publication of the results of his or her research, the physician is obliged to 
preserve the accuracy of the results. Reports of experimentation not in accordance 
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with the principles laid down in this Declaration should not be accepted for 
publication. 
9. In any research on human beings, each potential subject must be adequately 
informed of the aims, methods, anticipated benefits and potential hazards of the 
study and the discomfort it may entail. He or she should be informed that he or she is 
at liberty to abstain from participation in the study and that he or she is free to 
withdraw his or her consent to participation at any time. The physician should then 
obtain the subject's freely-given informed consent, preferably in writing. 
10. When obtaining informed consent for the research project the physician should be 
particularly cautious if the subject is in a dependent relationship to him or her or may 
consent under duress. In that case the informed consent should be obtained by a 
physician who is not engaged in the investigation and who is completely independent 
of this official relationship. 
11. In case of legal incompetence, informed consent should be obtained from the legal 
guardian in accordance with national legislation. Where physical or mental 
incapacity makes it impossible to obtain informed consent, or when the subject is a 
minor, permission from the responsible relative replaces that of the subject in 
accordance with national legislation. 
Whenever the minor child is in fact able to give a consent, the minor's consent must 
be obtained in addition to the consent of the minor's legal guardian. 
12. The research protocol should always contain a statement of the ethical considerations 
involved and should indicate that the principles enunciated in the present Declaration 
are complied with. 
II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE 
(Clinical research) 
1. In the treatment of the sick person, the physician must be free to use a new 
diagnostic and therapeutic measure, if in his or her judgement it offers hope of 
saving life, re-establishing health or alleviating suffering. 
2. The potential benefits, hazards and discomfort of a new method should be weighed 
against the advantages of the best current diagnostic and therapeutic methods. 
3. In any medical study, every patient - including those of a control group, if any - 
should be assured of the best proven diagnostic and therapeutic method. This does 
not exclude the use of inert placebo in studies where no proven diagnostic or 
therapeutic method exists. 
4. The refusal of the patient to participate in a study must never interfere with the 
physician–patient relationship. 
5. If the physician considers it essential not to obtain informed consent, the specific 
reasons for this proposal should be stated in the experimental protocol for 
transmission to the independent committee (I, 2). 
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6. The Physician can combine medical research with professional care, the objective 
being the acquisition of new medical knowledge, only to the extent that medical 
research is justified by its potential diagnostic or therapeutic value for the patient. 
III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN 
SUBJECTS 
(Non-clinical biomedical research) 
1. In the purely scientific application of medical research carried out on a human being, 
it is the duty of the physician to remain the protector of the life and health of that 
person on whom biomedical research is being carried out. 
2. The subjects should be volunteers - either healthy persons or patients for whom the 
experimental design is not related to the patient's illness. 
3. The investigator or the investigating team should discontinue the research if in 
his/her or their judgement it may, if continued, be harmful to the individual. 
In research on man, the interest of science and society should never take precedence over 
considerations related to the well being of the subject. 
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14. APPENDIX B: 
INVESTIGATOR'S AND SPONSOR'S RESPONSIBILITIES 
GUIDELINE FOR GOOD CLINICAL PRACTICE 
CPMP/ICH/1 35/95/Step5, Explanatory Note and Comments to the above, issued as 
CPMP/768/97 
1. INVESTIGATOR 
 
1.1 Investigator's Qualifications and Agreements 
 
1.1.1 The investigator(s) should be qualified by education, training, and experience to 
assume responsibility for the proper conduct of the trial, should meet all the 
qualifications specified by the applicable regulatory requirement(s), and should 
provide evidence of such qualifications through up-to-date curriculum vitae 
and/or other relevant documentation requested by the sponsor, the IRB/IEC, 
and/or the regulatory authority(ies). 
 
1.1.2 The investigator should be thoroughly familiar with the appropriate use of the 
investigational product(s), as described in the protocol, in the current 
Investigator's Brochure, in the product information and in other information 
sources provided by the sponsor. 
 
1.1.3 The investigator should be aware of, and should comply with, GCP and the 
applicable regulatory requirements. 
 
1.1.4 The investigator/institution should permit monitoring and auditing by the sponsor, 
and inspection by the appropriate regulatory authority(ies). 
 
1.1.5 The investigator should maintain a list of appropriately qualified persons to whom 
the investigator has delegated significant trial-related duties. 
 
1.2 Adequate Resources 
 
1.2.1 The investigator should be able to demonstrate (e.g., based on retrospective data) 
a potential for recruiting the required number of suitable subjects within the 
agreed recruitment period. 
 
1.2.2 The investigator should have sufficient time to properly conduct and complete the 
trial within the agreed trial period. 
 
1.2.3 The investigator should have available an adequate number of qualified staff and 
adequate facilities for the foreseen duration of the trial to conduct the trial 
properly and safely. 
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1.2.4 The investigator should ensure that all persons assisting with the trial are 
adequately informed about the protocol, the investigational product(s), and their 
trial-related duties and functions. 
 
1.3 Medical Care of Trial Subjects 
 
1.3.1 A qualified physician (or dentist when appropriate), who is an investigator or a 
sub-investigator for the trial, should be responsible for all trial-related medical (or 
dental) decisions. 
 
1.3.2 During and following a subject’s participation in a trial, the 
investigator/institution should ensure that adequate medical care is provided to a 
subject for any adverse events, including clinically significant laboratory values, 
related to the trial. The investigator/institution should inform a subject when 
medical care is needed for intercurrent illness(es) of which the investigator 
becomes aware. 
 
1.3.3 It is recommended that the investigator inform the subject's primary physician 
about the subject's participation in the trial if the subject has a primary physician 
and if the subject agrees to the primary physician being informed. 
 
1.3.4 Although a subject is not obliged to give his/her reason(s) for withdrawing 
prematurely from a trial, the investigator should make a reasonable effort to 
ascertain the reason(s), while fully respecting the subject's rights. 
 
1.4 Communication with IRB/IEC 
1.4.1 Before initiating a trial, the investigator/institution should have written and dated 
approval favourable opinion from the IRB/IEC for the trial protocol, written 
informed consent fomi, consent form updates, subject recruitment procedures 
(e.g., advertisements), and any other written information to be provided to 
subjects. 
 
1.4.2 As part of the investigator's/institution's written application to the IRB/IEC, the 
investigator/ institution should provide the IRB/IEC with a current copy of the 
Investigator's Brochure. If the Investigator's Brochure is updated during the trial, 
the investigator/institution should supply a copy of the updated Investigator's 
Brochure to the IRB/IEC. 
 
1.4.3 During the trial the investigator/institution should provide to the IRB/IEC all 
documents subject to review. 
 
1.5 Compliance with Protocol 
 
1.5.1 The investigator/institution should conduct the trial in compliance with the 
protocol agreed to by the sponsor and, if required, by the regulatory authority(ies) 
and which was given approval/favourable opinion by the IRB/IEC. The 
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investigator/institution and the sponsor should sign the protocol, or an alternative 
contract, to confirm agreement. 
 
1.5.2 The investigator should not implement any deviation from, or changes of the 
protocol without agreement by the sponsor and prior review and documented 
approval/favourable opinion from the IRB/IEC of an amendment, except where 
necessary to eliminate an immediate hazard(s) to trial subjects, or when the 
change(s) involves only logistical or administrative aspects of the trial (e.g., 
change in monitor(s), change of telephone number(s)). 
 
1.5.3 The investigator, or person designated by the investigator, should document and 
explain any deviation from the approved protocol. 
 
1.5.4 The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to trial subjects without prior IRB/IEC 
approval/favourable opinion. As soon as possible, the implemented deviation or 
change, the reasons for it and, if appropriate, the proposed protocol amendment(s) 
should be submitted: 
(a) to the IRB/IEC for review and approval/favourable opinion, 
(b) to the sponsor for agreement and, if required,  
(c) to the regulatory authority(ies). 
 
1.6 Investigational Product(s) 
 
1.6.1 Responsibility for investigational product(s) accountability at the trial site(s) rests 
with the investigator/institution. 
 
1.6.2 Where allowed/required, the investigator/institution may/should assign some or 
all of the investigator's/ institution's duties for investigational product(s) 
accountability at the trial site(s) to an appropriate pharmacist or another 
appropriate individual who is under the supervision of the investigator/institution. 
 
1.6.3 The investigator/institution and/or a pharmacist or other appropriate individual, 
who is designated by the investigator/institution, should maintain records of the 
product’s delivery to the trial site, the inventory at the site, the use by each subject 
and the return to the sponsor or alternative disposition of unused product(s). 
These records should include dates, quantities, batch/serial numbers, expiration 
dates (if applicable), and the unique code numbers assigned to the investigational 
product(s) and trial subjects. Investigators should maintain records that document 
adequately that the subjects were provided the doses specified by the protocol and 
reconcile all investigational product(s) received from the sponsor. 
 
1.6.4 The investigational product(s) should be stored as specified by the sponsor (see 
5.13.2 and 5.14.3) and in accordance with applicable regulatory requirement(s). 
 
1.6.5 The investigator should ensure that the investigational product(s) are used only in 
accordance with the approved protocol. 
Version V104 21-03-2013 77 
 
 MTBVAC Clinical Trial Protocol  
 
 
1.6.6 The investigator, or a person designated by the investigator/institution, should 
explain the correct use of the investigational product(s) to each subject and should 
check at intervals appropriate for the trial, that each subject is following the 
instructions properly. 
 
1.7 Randomization Procedures and Unblinding 
The investigator should follow the trial's randomization procedures, if any, and should 
ensure that the code is broken only in accordance with the protocol. If the trial is blinded, 
the investigator should promptly document and explain to the sponsor any premature 
unblinding (e.g., accidental unblinding, unblinding due to a serious adverse event) of the 
investigational product(s). 
1.8 Informed Consent of Trial Subjects 
 
1.8.1 In obtaining and documenting informed consent, the investigator should comply 
with the applicable regulatory requirement(s), and should adhere to GCP and to 
the ethical principles that have their origin in the Declaration of Helsinki. Prior to 
the beginning of the trial, the investigator should have the IRB/IEC's written 
approval/favourable opinion of the written informed consent form and any other 
written information to be provided to subjects. 
 
1.8.2 The written informed consent form and any other written information to be 
provided to subjects should be revised whenever important new information 
becomes available that may be relevant to the subject's consent. Any revised 
written informed consent form, and written information should receive the 
IRB/IEC's approval/favourable opinion in advance of use. The subject or the 
subject's legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the subject's 
willingness to continue participation in the trial. The communication of this 
information should be documented. 
 
1.8.3 Neither the investigator, nor the trial staff, should coerce or unduly influence a 
subject to participate or to continue to participate in a trial. 
 
1.8.4 None of the oral and written information concerning the trial, including the 
written informed consent form, should contain any language that causes the 
subject or the subject's legally acceptable representative to waive or to appear to 
waive any legal rights, or that releases or appears to release the investigator, the 
institution, the sponsor, or their agents from liability for negligence. 
 
1.8.5 The investigator, or a person designated by the investigator, should fully inform 
the subject or, if the subject is unable to provide informed consent, the subject’s 
legally acceptable representative, of all pertinent aspects of the trial including the 
written information and the approval/ favourable opinion by the IRB/IEC. 
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1.8.6 The language used in the oral and written information about the trial, including 
the written informed consent form, should be as non-technical as practical and 
should be understandable to the subject or the subject's legally acceptable 
representative and the impartial witness, where applicable. 
 
1.8.7 Before informed consent may be obtained, the investigator, or a person 
designated by the investigator, should provide the subject or the subject’s legally 
acceptable representative ample time and opportunity to inquire about details of 
the trial and to decide whether or not to participate in the trial. All questions about 
the trial should be answered to the satisfaction of the subject or the subject’s 
legally acceptable representative. 
 
1.8.8 Prior to a subject's participation in the trial, the written informed consent form 
should be signed and personally dated by the subject or by the subject's legally 
acceptable representative, and by the person who conducted the informed consent 
discussion.  
 
1.8.9 If a subject is unable to read or if a legally acceptable representative is unable to 
read, an impartial witness should be present during the entire informed consent 
discussion. After the written informed consent form and any other written 
information to be provided to subjects, is read and explained to the subject or the 
subject's legally acceptable representative, and after the subject or the subject's 
legally acceptable representative has orally consented to the subject's participation 
in the trial and, if capable of doing so, has signed and personally dated the 
informed consent form, the witness should sign and personally date the consent 
form. By signing the consent form, the witness attests that the information in the 
consent form and any other written information was accurately explained to, and 
apparently understood by, the subject or the subject's legally acceptable 
representative, and that informed consent was freely given by the subject or the 
subject's legally acceptable representative. 
 
1.8.10 Both the informed consent discussion and the written informed consent form and 
any other written information to be provided to subjects should include 
explanations of the following:  
(a) The trial involved research.  
(b) The purpose of the trial.  
(c) The trial treatment(s) and the probability for random assignment to each 
treatment.  
(d) The trial procedures to be followed, including all invasive procedures.  
(c) The subject’s responsibilities.  
 (f) Those aspects of the trial that are experimental.  
(g) The reasonably foreseeable risks or inconveniences to the subject and, when 
applicable, to an embryo, fetus, or nursing infant. 
(h) The reasonably expected benefits. When there is no intended clinical benefit 
to the subject, the subject should be made aware of this.  
(i) The alternative procedure(s) or course(s) of treatment that may be available to 
the subject and their important potential benefits and risks.  
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(j) The compensation and/or treatment available to the subject in the event of 
trial-related injury.  
(k) The anticipated prorated payment, if any, to the subject for participating in the 
trial.  
(1) The anticipated expenses, if any, to the subject for participating in the trial.  
(m) That the subject's participation in the trial is voluntary and that the subject 
may refuse to participate or withdraw from the trial, at any time, without penalty 
or loss of benefits to which the subject is otherwise entitled. 
(n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory 
authority(ies) will be granted direct access to the subject’s original medical 
records for verification of clinical trial procedures and/or data, without violating 
the confidentiality of the subject, to the extent permitted by the applicable laws 
and regulations and that, by signing a written informed consent form the subject 
or the subject’s legally acceptable representative is authorizing such access.  
(o) That records identifying the subject will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly 
available. If the results of the trial are published, the subject's identity will remain 
confidential.  
(p) That the subject or the subject's legally acceptable representative will be 
informed in a timely manner if information becomes available that may be 
relevant to the subject’s willingness to continue participation in the trial.  
(q) The person(s) to contact for further information regarding the trial and the 
rights of trial subjects, and whom to contact in the event of trial-related injury.  
(r) The foreseeable circumstances and/or reasons under which the subject's 
participation in the trial may be terminated. 
(s) The expected duration of the subject’s participation in the trial.  
(t) The approximate number of subjects involved in the trial. 
 
1.8.11 Prior to participation in the trial, the subject or the subject's legally acceptable 
representative should receive a copy of the signed and dated written informed 
consent form and any other written information provided to the subjects. During a 
subject's participation in the trial, the subject or the subject's legally acceptable 
representative should receive a copy of the signed and dated consent form updates 
and a copy of any amendments to the written information provided to subjects. 
 
1.8.12 When a clinical trial (therapeutic or non-therapeutic) includes subjects who can 
only be enrolled in the trial with the consent of the subject's legally acceptable 
representative (e.g., minors, or patients with severe dementia), the subject should 
be informed about the trial to the extent compatible with the subject's 
understanding and, if capable, the subject should sign and personally date the 
written informed consent. 
 
1.8.13 Except as described in 4.8.14, a non-therapeutic trial (i.e. a trial in which there is 
no anticipated direct clinical benefit to the subject), should be conducted in 
subjects who personally give consent and who sign and date the written informed 
consent form 
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1.8.14 Non-therapeutic trials may be conducted in subjects with consent of a legally 
acceptable representative provided the following conditions are fulfilled: 
(a) The objectives of the trial can not be met by means of a trial in subjects who 
can give informed consent personally.  
(b) The foreseeable risks to the subjects are low.  
(c) Tb c negative impact on the subject's well-being g is minimized and low.  
(d) The trial is not prohibited by law.  
(e) The approval/favourable opinion of the IRB/IEC is expressly sought on the 
inclusion of such subjects, and the written approval/ favourable opinion covers 
this aspect. 
Such trials, unless an exception is justified, should be conducted in patients 
having a disease or condition for which the investigational product is intended. 
Subjects in these trials should be particularly closely monitored and should be 
withdrawn if they appear to be unduly distressed. 
 
1.8.15 In emergency situations, when prior consent of the subject is not possible, the 
consent of the subject's legally acceptable representative, if present, should be 
requested. When prior consent of the subject is not possible, and the subject's 
legally acceptable representative is not available, enrolment of the subject should 
require measures described in the protocol and/or elsewhere, with documented 
approval/favourable opinion by the IRB/IEC, to protect the rights, safety and 
well-being of the subject and to ensure compliance with applicable regulatory 
requirements. The subject or the subject’s legally acceptable representative 
should be informed about the trial as soon as possible and consent to continue and 
other consent as appropriate (see 4.8. 10) should be requested. 
 
1.9 Records and Reports 
 
1.9.1 The investigator should ensure the accuracy, completeness, legibility, and 
timeliness of the data reported to the sponsor in the CRFs and in all required 
reports. 
 
1.9.2 Data reported on the CRF, that are derived from source documents, should be 
consistent with the source documents or the discrepancies should be explained. 
 
1.9.3 Any change or correction to a CRF should be dated, initialed, and explained (if 
necessary) and should not obscure the original entry (i.e. an audit trail should be 
maintained); this applies to both written and electronic changes or corrections 
(see 5.18.4 (n)). Sponsors should provide guidance to investigators and/or the 
investigators' designated representatives on making such corrections. Sponsors 
should have written procedures to assure that changes or corrections in CRFs 
made by sponsor's designated representatives are documented, are necessary, and 
are endorsed by the investigator. The investigator should retain records of the 
changes and corrections. 
 
1.9.4 The investigator/institution should maintain the trial documents as specified in 
Essential Documents for the Conduct of a Clinical Trial (see 8.) and as required 
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by the applicable regulatory requirement(s). The investigator/institution should 
take measures to prevent accidental or premature destruction of these documents. 
 
1.9.5 Essential documents should be retained until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no 
pending or contemplated marketing applications in an ICH region or at least 2 
years have elapsed since the formal discontinuation of clinical development of the 
investigational product. These documents should be retained for a longer period 
however if required by the applicable regulatory requirements or by an agreement 
with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained 
(see 5.5.12). 
 
1.9.6 The financial aspects of the trial should be documented in an agreement between 
the sponsor and the investigator/institution. 
 
1.9.7 Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the 
investigator/ institution should make available for direct access all requested 
trial-related records. 
 
1.10 Progress Reports 
 
1.10.1 The investigator should submit written summaries of the trial status to the 
IRB/IEC annually, or more frequently, if requested by the IRB/IEC. 
 
1.10.2 1.10.2 The investigator should promptly provide written reports to the sponsor, 
the IRB/IEC (see 3.3.8) and, where applicable, the institution on any changes 
significantly affecting the conduct of the trial, and/or increasing the risk to 
subjects. 
 
1.11 Safety Reporting 
 
1.11.1 All serious adverse events (SAES) should be reported immediately to the sponsor 
except for those SAEs that the protocol or other document (e.g., Investigator's 
Brochure) identifies as not needing immediate reporting. The immediate reports 
should be followed promptly by detailed, written reports. The immediate and 
follow-up reports should identify subjects by unique code numbers assigned to 
the trial subjects rather than by the subjects' names, personal identification 
numbers, and/or addresses. The investigator should also comply with the 
applicable regulatory requirement(s) related to the reporting of unexpected 
serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC. 
 
1.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as 
critical to safety evaluations should be reported to the sponsor according to the 
reporting requirements and within the time periods specified by the sponsor in the 
protocol. 
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1.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC 
with any additional requested information (e.g., autopsy reports and terminal 
medical reports). 
 
1.12 Premature Termination or Suspension of a Trial 
If the trial is prematurely terminated or suspended for any reason, the 
investigator/institution should promptly inform he trial subjects, should assure 
appropriate therapy and follow-up for the subjects, and, where required by the applicable 
regulatory requirement(s), should inform the regulatory authority(ies). In addition: 
1.12.1 If the investigator terminates or suspends a trial without prior agreement of the 
sponsor, the investigator should inform the institution where applicable, and the 
investigator/institution should promptly inform the sponsor and the IRB/IEC, and 
should provide the sponsor and the IRB/IEC a detailed written explanation of the 
termination or suspension. 
 
1.12.2 If the sponsor terminates or suspends a trial (see 5.21), the investigator should 
promptly inform the institution where applicable and the investigator/institution 
should promptly inform the IRB/IEC and provide the IRB/IEC a detailed written 
explanation of the termination or suspension. 
 
1.12.3 If the IRB/IEC terminates or suspends its approval/favourable opinion of a trial 
(see 3.1.2 and 3.3.9), the investigator should inform the institution where 
applicable and the investigator/institution should promptly notify the sponsor and 
provide the sponsor with a detailed written explanation of the termination or 
suspension. 
 
1.13 Final Report(s) by Investigator 
Upon completion of the trial, the investigator, where applicable, should inform the 
institution; the investigator/institution should provide the IRB/IEC with a summary of the 
trial's outcome, and the regulatory authority(ies) with any reports required. 
2. SPONSOR 
 
2.1 Quality Assurance and Quality Controls 
 
2.1.1 The sponsor is responsible for implementing and maintaining quality assurance 
and quality control systems with written SOPs to ensure that trials are conducted 
and data are generated, documented (recorded), and reported in compliance with 
the protocol, GCP, and the applicable regulatory requirement(s). 
 
2.1.2 The sponsor is responsible for securing agreement from all involved parties to 
ensure direct access (see 1.21) to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection 
by domestic and foreign regulatory authorities. 5.1.3 Quality control should be 
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applied to each stage of data handling to ensure that all data are reliable and have 
been processed correctly. 
 
2.1.3 Agreements, made by the sponsor with the investigator/institution and any other 
parties involved with the clinical trial, should be in writing, as part of the protocol 
or in a separate agreement. 
 
2.2 Contract Research Organization (CRO) 
 
2.2.1 A sponsor may transfer any or all of the sponsor's trial-related duties and 
functions to a CRO, but the ultimate responsibility for the quality and integrity of 
the trial data always resides with the sponsor. The CRO should implement quality 
assurance and quality control. 
 
2.2.2 Any trial-related duty and function that is transferred to and assumed by a CRO 
should be specified in writing. 
 
2.2.3 Any trial-related duties and functions not specifically transferred to and assumed 
by a CRO are retained by the sponsor. 
 
2.2.4 All references to a sponsor in this guideline also apply to a CRO to the extent that 
a CRO has assumed the trial related duties and functions of a sponsor. 
 
2.3 Medical Expertise 
The sponsor should designate appropriately qualified medical personnel who will be 
readily available to advise on trial related medical questions or problems. If necessary, 
outside consultant(s) may be appointed for this purpose. 
2.4 Trial Design 
 
2.4.1 The sponsor should utilize qualified individuals (e.g. biostatisticians, clinical 
pharmacologists, and physicians) as appropriate, throughout all stages of the trial 
process, from designing the protocol and CRFs and planning the analyses to 
analyzing and preparing interim and final clinical trial reports. 
 
2.4.2 For further guidance: Clinical Trial Protocol and Protocol Amendment(s) (see 6.), 
the ICH Guideline for Structure and Content of Clinical Study Reports, and other 
appropriate ICH guidance on trial design, protocol and conduct. 
 
2.5 Trial Management Data Handling, and Record Keeping 
 
2.5.1 The sponsor should utilize appropriately qualified individuals to supervise the 
overall conduct of the trial, to handle the data, to verify the data, to conduct the 
statistical analyses, and to prepare the trial reports. 
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2.5.2 The sponsor may consider establishing an independent data-monitoring 
committee (IDMC) to assess the progress of a clinical trial, including the safety 
data and the critical efficacy endpoints at intervals, and to recommend to the 
sponsor whether to continue, modify, or stop a trial. The IDMC should have 
written operating procedures and maintain written records of all its meetings. 
 
2.5.3 When using electronic trial data handling and/or remote electronic trial data 
systems, the sponsor should: 
a) Ensure and document that the electronic data processing system(s) conforms to 
the sponsor's established requirements for completeness, accuracy, reliability, and 
consistent intended performance (i.e. validation). 
b) Maintains SOPs for using these systems. c) Ensure that the systems are 
designed to permit data changes in such a way that the data changes are 
documented and that there is no deletion of entered data (i.e. maintain an audit 
trail, data trail, edit trail). 
d) Maintain security system that prevents unauthorized access to the data.  
e) Maintain a list of the individuals who are authorized to make data changes (see 
4.1.5 and 4.9.3). 
f) Maintain adequate backup of the data. 
g) Safeguard the blinding, if any (e.g. maintain the blinding during data entry and 
processing). 
 
2.5.4 If data are transformed during processing, it should always be possible to 
compare the original data and observations with the processed data. 
 
2.5.5 The sponsor should use an unambiguous subject identification code (see 1.58) 
that allows identification of all the data reported for each subject. 
 
2.5.6 The sponsor, or other owners of the data, should retain all of the sponsor-specific 
essential documents pertaining to the trial (see 8. Essential Documents for the 
Conduct of a Clinical Trial). 
 
2.5.7 The sponsor should retain all sponsor-specific essential documents in 
conformance with the applicable regulatory requirement(s) of the country (ies) 
where the product is approved, and/or where the sponsor intends to apply for 
approval(s). 
 
2.5.8 If the sponsor discontinues the clinical development of an investigational product 
(i.e. for any or all indications, routes of administration, or dosage forms), the 
sponsor should maintain all sponsor specific essential documents for at least 2 
years after formal discontinuation or in conformance with the applicable 
regulatory requirement(s). 
 
2.5.9 If the sponsor discontinues the clinical development of an investigational product 
the sponsor should notify all the trial investigators/institutions and all the 
regulatory authorities. 
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2.5.10 Any transfer of ownership of the data should be reported to the appropriate 
authority(ies), as required by the applicable regulatory requirement(s). 
 
2.5.11 2.5. 11 The sponsor specific essential documents should be retained until at least 
2 years after the last approval of a marketing application in an ICH region and 
until there are no pending or contemplated marketing applications in an ICH 
region or at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These documents should be retained 
for a longer period however if required by the applicable regulatory 
requirement(s) or if needed by the sponsor. 
 
2.5.12 The sponsor should inform the investigator(s)/institution(s) in writing of the need 
for record retention and should notify the investigator(s)/institution(s) in writing 
when the trial related records are no longer needed. 
 
2.6 Investigator Selection 
 
2.6.1 The sponsor is responsible for selecting the investigator(s)/institution(s). Each 
investigator should be qualified by training and experience and should have 
adequate resources (see 4.1, 4.2) to properly conduct the trial for which the 
investigator is selected. If organization of a coordinating committee and/or 
selection of coordinating investigator(s) are to be utilized in multicentre trials, 
their organization and/or selection is the sponsor’s responsibility. 
 
2.6.2 Before entering an agreement with an investigator/institution to conduct a trial, 
the sponsor should provide the investigator(s)/institution(s) with the protocol and 
an up-to date Investigator's Brochure, and should provide sufficient time for the 
investigator/institution to review the protocol and the information provided. 
 
2.6.3 The sponsor should obtain the investigator's/institution's agreement: 
(a) to conduct the trial in compliance with GCP, with the applicable regulatory 
requirement(s) (see 4.1.3), and with the protocol agreed to by the sponsor and 
given approval/favourable opinion by the IRB/IEC (see 4.5. 1); 
(b) to comply with procedures for data recording/reporting; 
(c) to permit monitoring, auditing and inspection (see 4.1.4) and 
(d) to retain the trial related essential documents until the sponsor informs the 
investigator/institution these documents are no longer needed (see 4.9.4 and 
5.5.12). 
 
2.6.4 The sponsor and the investigator/institution should sign the protocol, or an 
alternative document to confirm this agreement. 
 
2.7 Allocation of Responsibilities 
Prior to initiating a trial, the sponsor should define, establish, and allocate all trial-related 
duties and functions. 
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2.8 Compensation to Subjects and Investigators 
 
2.8.1 If required by the applicable regulatory requirement(s), the sponsor should 
provide insurance or should indemnify (legal and financial coverage) the 
investigator/the institution against claims arising from the trial, except for claims 
that arise from malpractice and/or negligence. 
 
2.8.2 The sponsor's policies and procedures should address the costs of treatment of 
trial subjects in the event of trial-related injuries in accordance with the applicable 
regulatory requirement(s). 
 
2.8.3 When trial subjects receive compensation, the method and manner of 
compensation should comply with applicable regulatory requirement(s). 
 
2.9 Financing 
The financial aspects of the trial should be documented in an agreement between the 
sponsor and the investigator/institution. 
2.10 Notification/Submission to Regu1atory Authority(ies) 
Before initiating the clinical trial(s), the sponsor (or the sponsor and the investigator, if 
required by the applicable regulatory requirement(s) should submit any required 
application(s) to the appropriate authority(ies) for review, acceptance, and/or permission 
(as required by the applicable regulatory requirement(s)) to begin the trial(s). Any 
notification/submission should be dated and contain sufficient information to identify the 
protocol. 
2.11 Confirmation of Review by IRB/IEC 
 
2.11.1 The sponsor should obtain from the investigator/institution: 
a) The name and address of the investigator's/institution's IRB/IEC.  
b) A statement obtained from the IRB/IEC that it is organized and operates 
according to GCP and the applicable laws and regulations. 
c) Documented IRB/IEC approval/favourable opinion and, if requested by the 
sponsor, a  current copy of protocol, written informed consent form(s) and any 
other written  information to be provided to subjects, subject recruiting 
procedures, and any other  documents that the IRB/IEC may have requested. 
 
2.11.2 If the IRB/IEC conditions its approval/favourable opinion upon change(s) in any 
aspect of the trial, such as modification(s) of the protocol, written informed 
consent form and any other written information to be provided to subjects, and/or 
other procedures, the sponsor should obtain from the investigator/institution a 
copy of the modification(s) made and the date approval/favourable opinion was 
given by the IRB/IEC. 
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2.11.3 The sponsor should obtain from the investigator/institution documentation and 
dates of any IRB/IEC reapprovals/re-evaluations with favourable opinion, and of 
any withdrawals or suspensions of approval/favourable opinion. 
 
2.12 2.12 Information on Investigational Product(s) 
 
2.12.1 When planning trials, the sponsor should ensure that sufficient safety and efficacy 
data from nonclinical studies and/or clinical trials are available to support human 
exposure by the route, at the dosages, for the duration, and in the trial population 
to be studied. 
 
2.12.2 The sponsor should update the Investigator's Brochure as significant new 
information becomes available (see 7. Investigator's Brochure). 
 
2.13 Manufacturing, Packaging, Labelling, and Coding Investigational Product(s) 
 
2.13.1 The sponsor should ensure that the investigational product(s) (including active 
comparator(s) and placebo, if applicable) is characterized as appropriate to the 
stage of development of the product(s), is manufactured in accordance with any 
applicable GW, and is coded and labelled in a manner that protects the blinding, 
if applicable. In addition, the labelling should comply with applicable regulatory 
requirement(s). 
 
2.13.2 The sponsor should determine, for the investigational product(s), acceptable 
storage temperatures, storage conditions (e.g. protection from light), storage 
times, reconstitution fluids and procedures, and devices for product infusion, if 
any. The sponsor should inform all involved parties (e.g. monitors, investigators, 
pharmacists, storage managers) of these determinations. 
 
2.13.3 The investigational product(s) should be packaged to prevent contamination and 
unacceptable deterioration during transport and storage. 
 
2.13.4 In blinded trials, the coding system for the investigational product(s) should 
include a mechanism that permits rapid identification of the product(s) in case of 
a medical emergency, but does not permit undetectable breaks of the blinding. 
 
2.13.5 If significant formulation changes are made in the investigational or comparator 
product(s) during the course of clinical development the results of any additional 
studies of the formulated product(s) (e.g. stability, dissolution rate, 
bioavailability) needed to assess whether these changes would significantly alter 
the pharmacokinetic profile of the product should be available prior to the use of 
the new formulation in clinical trials. 
 
2.14 Supplying and Handling Investigational Product(s) 
 
2.14.1 The sponsor is responsible for supplying the investigator(s)/institution(s) with the 
investigational product(s). 
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2.14.2 The sponsor should not supply an investigator/institution with the investigational 
product(s) until the sponsor obtains all required documentation (e.g. 
approval/favourable opinion from IRB/IEC and regulatory authority(ies)). 
 
2.14.3 The sponsor should ensure that written procedures include instructions that the 
investigator/institution should follow for the handling and storage of 
investigational product(s) for the trial and documentation thereof. The procedures 
should address adequate and safe receipt, handling, storage, dispensing, retrieval 
of unused product from subjects, and return of unused investigational product(s) 
to the sponsor (or alternative disposition if authorized by the sponsor and in 
compliance with the applicable regulatory requirement(s)). 
 
2.14.4 The sponsor should: 
 
a) Ensure timely delivery of investigational product(s) to the investigator(s). 
b) Maintain records that document shipment receipt disposition, return, and 
destruction of the investigational product(s) (see 8. Essential Documents for the 
Conduct of a Clinical Trial). 
c) Maintain a system for retrieving investigational products and documenting this 
retrieval (e.g. for deficient product recall, reclaim after trial completion, expired 
product reclaim). 
d) Maintain a system for the disposition of unused investigational product(s) and 
for the documentation of this disposition. 
 
2.14.5 The sponsor should: 
 
a) Take steps to ensure that the investigational product(s) are stable over the 
period of use. 
b) Maintain sufficient quantities of the investigational product(s) used in the trials 
to reconfirm specifications, should this become necessary, and maintain records 
of batch sample analyses and characteristics. To the extent stability permits, 
samples should be retained either until the analyses of the trial data are complete 
or as required by the applicable regulatory requirement(s), whichever represents 
the longer retention period. 
 
2.15 Record Access 
 
2.15.1  
 
The sponsor should ensure that it is specified in the protocol or other written agreement 
that the investigator(s)/institution(s) provide direct access to source data/documents for 
trial-related monitoring, audits, IRB/IEC review, and regulatory inspection. 
 
2.15.2  
The sponsor should verify that each subject has consented, in writing, to direct access to 
his/her original medical records for trial-related monitoring, audit, IRB/IEC review, and 
regulatory inspection. 
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2.16 Safety Information 
 
2.16.1  
 
The sponsor is responsible for the ongoing safety evaluation of the investigational 
product(s). 
 
2.16.2  
 
The sponsor should promptly notify all concerned investigator(s)/institution(s) and the 
regulatory authority (ies) of findings that could affect adversely the safety of subjects, 
impact the conduct of the trial, or alter the IRB/IEC's approval/favourable opinion to 
continue the trial. 
 
2.17 Adverse Drug Reaction Reporting 
 
2.17.1  
 
The sponsor should expedite the reporting to all concerned investigator(s)/institutions(s), 
to the IRB(s)/IEC(s), where required, and to the regulatory authority(ies) of all adverse 
drug reactions (ADRS) that are both serious and unexpected. 
 
2.17.2  
 
Such expedited reports should comply with the applicable regulatory requirement(s) and 
with the ICH Guideline for Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting. 
 
2.17.3  
 
The sponsor should submit to the regulatory authority(ies) all safety updates and periodic 
reports, as required by applicable regulatory requirement(s). 
 
2.18 Monitoring 
 
2.18.1 Purpose 
 
The purposes of trial monitoring are to verify that:  
a) The rights and well-being of human subjects are protected.  
b) The reported trial data are accurate, complete, and verifiable from source 
documents.  
c) The conduct of the trial is in compliance with the currently approved protocol/ 
amendment(s), with GCP, and with the applicable regulatory requirement(s). 
 
2.18.2 Selection and Qualifications of Monitors  
a) Monitors should be appointed by the sponsor.  
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b) Monitors should be appropriately trained, and should have the scientific and/or 
clinical knowledge needed to monitor the trial adequately. Monitors qualifications 
should be documented. 
c) Monitors should be thoroughly familiar with the investigational product(s), the 
protocol, written informed consent form and any other written information to be 
provided to subjects, the sponsors SOPS, GCP, and the applicable regulatory 
requirement(s). 
 
2.18.3 Extent and Nature of Monitoring 
 
The sponsor should ensure that the trials are adequately monitored. The sponsor should 
determine the appropriate extent and nature of monitoring. The determination of the 
extent and nature of monitoring should be based on considerations such as the objective, 
purpose, design, complexity, blinding, size, and endpoints of the trial. In general there is 
a need for on-site monitoring, before, during, and after the trial; however in exceptional 
circumstances the sponsor may determine that central monitoring in conjunction with 
procedures such as investigator's training and meetings, and extensive written guidance 
can assure appropriate conduct of the trial in accordance with GCP. Statistically 
controlled sampling may be an acceptable method for selecting the data to be verified. 
 
2.18.4 Monitor's Responsibilities 
 
The monitor(s) in accordance with the sponsor's requirements should ensure that the trial 
is conducted and documented properly by carrying out the following activities when 
relevant and necessary to the trial and the trial site: 
 
a) Acting as the main line of communication between the sponsor and the 
investigator. 
b) Verifying that the investigator has adequate qualifications and resources (see 
4.1, 4.2, 5.6) and remain adequate throughout the trial period, that facilities, 
including laboratories, equipment, and staff, are adequate to safely and properly 
conduct the trial and remain adequate throughout the trial period. 
c) Verifying, for the investigational product(s): 
i) That storage times and conditions are acceptable, and that supplies are 
sufficient throughout the trial. 
ii) That the investigational product(s) are supplied only to subjects who 
are eligible to receive it and at the protocol specified dose(s). 
iii) That subjects are provided with necessary instruction on properly 
using, handling, storing, and returning the investigational product(s). 
iv) That the receipt, use, and return of the investigational product(s) at the 
trial sites are controlled and documented adequately. 
v) That the disposition of unused investigational product(s) at the trial 
sites complies with applicable regulatory requirement(s) and is in 
accordance with the sponsor. 
d) Verifying that the investigator follows the approved protocol and all approved 
amendment(s), if any. 
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e) Verifying that written informed consent was obtained before each subject’s 
participation in the trial. 
f) Ensuring that the investigator receives the current Investigator's Brochure, all 
documents, and all trial supplies needed to conduct the trial properly and to 
comply with the applicable regulatory requirement(s). 
g) Ensuring that the investigator and the investigator's trial staff are adequately 
informed about the trial. 
h) Verifying that the investigator and the investigator's trial staff are performing 
the specified trial functions, in accordance with the protocol and any other written 
agreement between the sponsor and the investigator/institution, and have not 
delegated these functions to unauthorized individuals.  
i) Verifying that the investigator is enrolling only eligible subjects.  
j) Reporting the subject recruitment rate. 
k) Verifying that source documents and other trial records are accurate, complete, 
kept up-to-date and maintained. 
1) Verifying that the investigator provides all the required reports, notifications, 
applications, and submissions, and that these documents are accurate, complete, 
timely, legible, dated, and identify the trial.  
m) Checking the accuracy and completeness of the CRF entries, source 
documents and other trial related records against each other. The monitor 
specifically should verify that: 
 i) The data required by the protocol are reported accurately on the CRFs 
and are consistent with the source documents. 
ii) Any dose and/or therapy modifications are well documented for each of 
the trial subjects. 
iii) Adverse events, concomitant medications and intercurrent illnesses are 
reported in accordance with the protocol on the CRFs. 
iv) Missed Visits, tests that are not conducted, and examinations that are 
not performed are clearly reported as such on the CRFs. 
v) All withdrawals and dropouts of enrolled subjects from the trial are 
reported and explained on the CRFs.  
n) Informing the investigator of any CRF entry error, omission, or illegibility. The 
monitor should ensure that appropriate corrections, additions, or deletions are 
made, dated, explained (if necessary), and initialed by the investigator or by a 
member of the investigator's trial staff who is authorized to initial CRF changes 
for the investigator. This authorization should be documented.  
o) Determining whether all adverse events (AEs) are appropriately reported 
within the time periods required by GCP, the protocol, the IRB/IEC, the sponsor, 
and the applicable regulatory requirement(s). p) Determining whether the 
investigator is maintaining the essential documents (see 8. Essential Documents 
for the Conduct of a Clinical Trial). q) Communicating deviations from the 
protocol, SOPS, GCP, and the applicable regulatory requirements to the 
investigator and taking appropriate action designed to prevent recurrence of the 
detected deviations. 
 
2.18.5 Monitoring Procedures 
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The monitor(s) should follow the sponsor established written SOPs as well as those 
procedures that are specified by the sponsor for monitoring a specific trial. 
 
2.18.6 Monitoring Report  
 
a) The monitor should submit a written report to the sponsor after each trial-site 
visit or trial-related communication. b) Reports should include the date, site, 
name of the monitor, and name of the investigator or other individual(s) 
contacted. 
c) Reports should include a summary of what the monitor reviewed and the 
monitor's statements concerning the significant findings/facts, deviations and 
deficiencies, conclusions, actions taken or to be taken and/or actions 
recommended to secure compliance. 
d) The review and follow-up of the monitoring report with the sponsor should be 
documented by the sponsor’s designated representative. 
 
2.19 Audit 
If or when sponsors perform audits, as part of implementing quality assurance, they 
should consider: 
2.19.1 Purpose 
 
The purpose of a sponsor's audit, which is independent of and separate from routine 
monitoring or quality control functions, should be to evaluate trial conduct and 
compliance with the protocol, SOPS, GCP, and the applicable regulatory requirements. 
 
2.19.2 Selection and Qualification of Auditors 
 
a) The sponsor should appoint individuals, who are independent of the clinical 
trials/systems, to conduct audits. 
b) The sponsor should ensure that the auditors are qualified by training and 
experience to conduct audits properly. An auditor’s qualifications should be 
documented. 
 
2.19.3 Auditing Procedures 
 
a) The sponsor should ensure that the auditing of clinical trials/systems is 
conducted in accordance with the sponsor's written procedures on what to audit 
how to audit, the frequency of audits, and the form and content of audit reports. 
b) The sponsor's audit plan and procedures for a trial audit should be guided by 
the importance of the trial to submissions to regulatory authorities, the number of 
subjects in the trial, the type and complexity of the trial, the level of risks to the 
trial subjects, and any identified problem(s). 
c) The observations and findings of the auditor(s) should be documented. 
d) To preserve the independence and value of the audit function, the regulatory 
authority(ies) should not routinely request the audit reports. Regulatory 
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authority(ies) may seek access to an audit report on a case by case basis when 
evidence of serious GCP non-compliance exists, or in the course of legal 
proceedings. 
e) When required by applicable law or regulation, the sponsor should provide an 
audit certificate. 
 
2.20 Non-compliance 
 
2.20.1 Noncompliance with the protocol, SOPS, GCP, and/or applicable regulatory 
requirement(s) by an investigator/institution, or by number(s) of the sponsor's 
staff should lead to prompt action by the sponsor to secure compliance. 
 
2.20.2 If the monitoring and/or auditing identify serious and/or persistent noncompliance 
on the part of an investigator/institution, the sponsor should terminate the 
investigator's/institutions participation in the trial. When an 
investigator's/institutions participation is terminated because of noncompliance, 
the sponsor should notify promptly the regulatory authority(ies). 
 
2.21 Premature Termination or Suspension of a Trial 
If a trial is prematurely terminated or suspended, the sponsor should promptly inform the 
investigators/institutions, and the regulatory authority(ies) of the termination or 
suspension and the reason(s) for the termination or suspension. The IRB/IEC should also 
be informed promptly and provided the reason(s) for the termination or suspension by the 
sponsor or by the investigator/institution, as specified by the applicable regulatory 
requirement(s). 
2.22 Clinical Trial/Study Reports 
Whether the trial is completed or prematurely terminated, the sponsor should ensure that 
the clinical trial reports are prepared and provided to the regulatory agency(ies) as 
required by the applicable regulatory requirement(s). The sponsor should also ensure that 
the clinical trial reports in marketing applications meet the standards of the ICH 
Guideline for Structure and Content of Clinical Study Reports. (NOTE: The ICH 
Guideline for Structure and Content of Clinical Study Reports specifies that abbreviated 
study reports may be acceptable in certain cases.)  
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15. APPENDIX C : 
VACCINE SUPPLIES, PACKAGING AND 
ACCOUNTABILITY 
1. Vaccine and/or other supplies 
BIOFABRI will supply the following amounts of of study vaccines and/or other supplies, 
sufficient to administer the corresponding doses to all subjects as described in the present 
protocol. 
• 18 vials of MTBVAC, 10 standard doses per vial, will be sent 
• The corresponding MTBVAC diluent vials for reconstituting the vaccine 
• The corresponding MTBVAC excipient solution vials (4.5 mL) for making the 
dilutions.  
 
2.  Secondary packaging  
The vaccines will be packed in labelled boxes. The box label will contain, as a minimum, 
the following information: study number, lot number, instructions for vaccine 
administration, the statement “contains GMO” and any other relevant regulatory 
requirements. 
3. Vaccine shipment  
from BIOFABRI  to Centre Hospitalier Universitaire Vaudois (CHUV) 
 
Study vaccines will be sent from BIOFABRI TO Centre Hospitalier Universitaire 
Vaudois (CHUV) after the GMP and GCP releases which are documented and 
archived. 
Shipments are made in tamper evident parcels containing: 
• a copy of Certificate of Analysis if required by local regulatory authorities 
• a Delivery Note describing: study and centre number, investigational site name 
and address, recipient, products name, quantity supplied, lot numbers, expiry 
dates and storage requirements 
• 2 temperature control devices 
All shipments shall be received and acknowledged by the appropriate recipient at Centre 
Hospitalier Universitaire Vaudois (CHUV).  
The following documents should be completed and returned to BIOFABRI, S.L. on 
reception of vaccine shipment: 
• Delivery Note 
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• Temperature control devices. 
These documents and devices should then be returned to:  
Attention of Dr Eugenia Puentes 
Qualified Person 
BIOFABRI , S.L 
Fax : +34 986 345 201 
E-mail: e.puentes@biofabri.es 
Temperature recording charts will be obtained at BIOFABRI to check that cold chain has 
not been broken. Study vaccines will not be used at Centre Hospitalier Universitaire 
Vaudois (CHUV) until confirmation of suitability is provided by BIOFABRI. In case of 
any temperature deviation, the official approval for the use of vaccine must be obtained 
from BIOFABRI.  
4. Vaccine accountability 
At all times the figures on supplied, used and remaining vaccine doses should match. At 
the end of the study, it must be possible to reconcile delivery records with those of used 
and unused stocks.  An explanation must be given of any discrepancies. 
After approval from BIOFABRI, used and unused study vaccine vials/syringes should be 
destroyed at the study site using locally approved biosafety procedures and 
documentation unless otherwise described in the protocol. If no adequate biosafety 
procedures are available at the study site, the used and unused vaccine vials/syringes are 
to be returned to an appropriate BIOFABRI site for destruction.  
5. Transfers of clinical vaccines or products from country medical department or 
dispatch centre to study sites or between sites 
Not applicable. 
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